Electrical ablation devices and methods

Information

  • Patent Grant
  • 10278761
  • Patent Number
    10,278,761
  • Date Filed
    Thursday, January 14, 2016
    8 years ago
  • Date Issued
    Tuesday, May 7, 2019
    5 years ago
Abstract
An ablation device may generally comprise a first electrode, a plurality of second electrodes, and a grounding pad. Each of the plurality of second electrodes may comprise a first conductive section, a second conductive section, and a non-conductive section between the first conductive section and the second conductive section. The first electrode and each of the plurality of second electrodes may be coupled to an energy source delivering a series of electrical pulses to tissue to induce cell necrosis by irreversible electroporation.
Description
BACKGROUND

Electrical ablation therapy has been used in medicine for the treatment of undesirable tissue, such as, for example, diseased tissue, cancer, malignant and benign tumors, masses, lesions, and other abnormal tissue growths. Apparatuses, systems, and methods for conventional ablation therapies may include electrical ablation therapies, such as, for example, high temperature thermal therapies including, focused ultrasound ablation, radiofrequency (RF) ablation, and interstitial laser coagulation, chemical therapies in which chemical agents are injected into the undesirable tissue to cause ablation, surgical excision, cryotherapy, radiation, photodynamic therapy, Moh's micrographic surgery, topical treatments with 5-fluorouracil, and laser ablation.


Conventional electrical ablation therapies may suffer from some of the following limitations: cost, length of recovery, permanent damage to healthy tissue, and extraordinary pain inflicted on the patient. One drawback of conventional electrical ablation therapies may be high current density at the electrode tip. High current density at the electrode tip may contribute to thermal necrosis to tissue surrounding the electrode tip. High current density at the electrode tip may also contribute to induced muscle contractions in skeletal muscle, cardiac muscle, and/or smooth muscle due to the delivery of electrical pulses to the undesirable tissue during treatment. For example, the electrical pulses may induce strong and painful muscle contractions in skeletal muscles in proximity to the electrode. The induced muscle contraction may cause unwanted damage to the tissue due to electrode movement. The induced muscle contractions may also be problematic when provoked in heart muscle. Accordingly, electrical ablation apparatuses, systems, and methods for the treatment of undesirable tissue having reduced current density at the electrode tip are desirable.





FIGURES

The various embodiments of electrical ablation devices and methods thereof described herein may be better understood by considering the following description in conjunction with the accompanying drawings.



FIG. 1 illustrates an electrical ablation system according to certain embodiments described herein.



FIGS. 2A-B illustrate an electrical ablation system according to certain embodiments described herein.



FIG. 3 illustrates an electrical ablation system according to certain embodiments described herein.



FIG. 4 illustrates an electrical ablation system according to certain embodiments described herein.



FIG. 5 is graphical representation of a cell necrosis by irreversible electroporation according to certain embodiments described herein.



FIG. 6 is graphical representation of a cell necrosis by irreversible electroporation according to certain embodiments described herein.





DESCRIPTION

Various embodiments are directed to electrical ablation apparatuses, systems, and methods for the treatment of undesirable tissue having reduced current density at the electrode tip.


This disclosure describes various elements, features, aspects, and advantages of various embodiments of electrical ablation devices and methods thereof. It is to be understood that certain descriptions of the various embodiments have been simplified to illustrate only those elements, features and aspects that are relevant to a more clear understanding of the disclosed embodiments, while eliminating, for purposes of brevity or clarity, other elements, features and aspects. Any references to “various embodiments,” “some embodiments,” “one embodiment,” or “an embodiment” generally means that a particular element, feature and/or aspect described in the embodiment is included in at least one embodiment. The phrases “in various embodiments,” “in some embodiments,” “in one embodiment,” or “in an embodiment” may not refer to the same embodiment. Persons having ordinary skill in the art, upon considering the description herein, will recognize that various combinations or sub-combinations of the various embodiments and other elements, features, and aspects may be desirable in particular implementations or applications. However, because such other elements, features, and aspects may be readily ascertained by persons having ordinary skill in the art upon considering the description herein, and are not necessary for a complete understanding of the disclosed embodiments, a description of such elements, features, and aspects may not be provided. As such, it is to be understood that the description set forth herein is merely exemplary and illustrative of the disclosed embodiments and is not intended to limit the scope of the invention as defined solely by the claims.


All numerical quantities stated herein are approximate unless stated otherwise, meaning that the term “about” may be inferred when not expressly stated. The numerical quantities disclosed herein are to be understood as not being strictly limited to the exact numerical values recited. Instead, unless stated otherwise, each numerical value is intended to mean both the recited value and a functionally equivalent range surrounding that value. At the very least, and not as an attempt to limit the application of the doctrine of equivalents to the scope of the claims, each numerical parameter should at least be construed in light of the number of reported significant digits and by applying ordinary rounding techniques.


Notwithstanding the approximations of numerical quantities stated herein, the numerical quantities described in specific examples of actual measured values are reported as precisely as possible.


All numerical ranges stated herein include all sub-ranges subsumed therein. For example, a range of “1 to 10” is intended to include all sub-ranges between and including the recited minimum value of 1 and the recited maximum value of 10. Any maximum numerical limitation recited herein is intended to include all lower numerical limitations. Any minimum numerical limitation recited herein is intended to include all higher numerical limitations.


As generally used herein, the terms “proximal” and “distal” generally refer to a clinician manipulating one end of an instrument used to treat a patient. The term “proximal” generally refers to the portion of the instrument closest to the clinician. The term “distal” generally refers to the portion located furthest from the clinician. It will be further appreciated that for conciseness and clarity, spatial terms such as “vertical,” “horizontal,” “up,” and “down” may be used herein with respect to the illustrated embodiments. However, surgical instruments may be used in many orientations and positions, and these terms are not intended to be limiting and absolute.


In certain embodiments, electrical ablation devices may generally comprise one or more electrodes configured to be positioned into or proximal to undesirable tissue in a tissue treatment region (e.g., a target site or a worksite). The tissue treatment region may have evidence of abnormal tissue growth. In general, the electrodes may comprise an electrically conductive portion (e.g., medical grade stainless steel, gold plated, etc.) and may be configured to electrically couple to an energy source. The electrodes may have a diameter or radius from 0.5 mm to 1.5 mm, such as, for example, 0.5 mm, 0.75 mm, 1 mm, and 1.5 mm. Once the electrodes are positioned into or proximal to the undesirable tissue, an energizing potential may be applied to the electrodes to create an electric field to which the undesirable tissue is exposed. The energizing potential (and the resulting electric field) may be characterized by various parameters, such as, for example, frequency, amplitude, pulse width (duration of a pulse or pulse length), and/or polarity. Depending on the diagnostic or therapeutic treatment to be rendered, a particular electrode may be configured either as an anode or a cathode, or a plurality of electrodes may be configured with at least one electrode configured as an anode and at least one other electrode configured as a cathode. Regardless of the initial polarity configuration, the polarity of the electrodes may be reversed by reversing the polarity of the output of the energy source.


In certain embodiments, a suitable energy source may comprise an electrical waveform generator. The electrical waveform generator may be configured to create an electric field that is suitable to create irreversible electroporation in undesirable tissue at various electric field amplitudes and durations. The energy source may be configured to deliver electrical pulses in the form of direct-current (DC) and/or alternating-current (AC) voltage potentials (e.g., time-varying voltage potentials) to the electrodes. The energy source may also be configured to reverse the potential between the electrodes. The electrical pulses may be characterized by various parameters, such as, for example, frequency, amplitude, pulse width, polarity, total number of pulses, and delay between pulses bursts. The undesirable tissue may be ablated by exposure to the electric potential difference across the electrodes.


In certain embodiments, the apparatuses, systems, and methods may be configured for minimally invasive ablation treatment of undesirable tissue through the use of irreversible electroporation. Minimally invasive ablation treatment of undesirable tissue may be characterized by the ability to ablate undesirable tissue in a controlled and focused manner having reduced or no thermally damaging effects to the surrounding healthy tissue. The apparatuses, systems, and methods may be configured to ablate undesirable tissue through the use of electroporation or electropermeabilization. Electroporation refers to the application of electric pulses to a cell membrane to cause an increase in the permeabilization of the cell membrane. The external electric field (i.e., electric potential/per unit length) applied to the cell may significantly increase the electrical conductivity and permeability of the plasma in the cell membrane.


More specifically, the apparatuses, systems, and methods may be configured to ablate undesirable tissue through the use of irreversible electroporation. Irreversible electroporation refers to the application of an electric field of a specific magnitude and duration to a cell membrane such that the permeabilization of the cell membrane cannot be reversed. One of the primary parameters affecting the transmembrane potential is the potential difference across the cell membrane. The destabilizing potential may form pores in the cell membrane when the potential across the cell membrane exceeds its dielectric strength causing the cell to die under a process known as apoptosis and/or necrosis. Irreversible electroporation may lead to cell death without inducing a significant amount of heat in the cell membrane.


The application of irreversible electroporation pulses to cells may be an effective way for ablating large volumes of undesirable tissue with no or minimal detrimental thermal effects to the surrounding healthy tissue. Without wishing to be bound to any particular theory, it is believed that irreversible electroporation destroys cells with no or minimal heat, and thus, may not destroy the cellular support structure or regional vasculature. A destabilizing irreversible electroporation pulse, suitable to cause cell death without inducing a significant amount of thermal damage to the surrounding healthy tissue, may have amplitude in the range of several hundred to several thousand volts and may be generally applied across biological membranes over a distance of several millimeters, for example, for a relatively long duration of 1 μs to 100 ms. Thus, the undesirable tissue may be ablated in-vivo through the delivery of destabilizing electric fields by quickly causing cell necrosis.


The apparatuses, systems, and methods for electrical ablation therapy may be adapted for use in minimally invasive surgical procedures to access the tissue treatment region in various anatomic locations, such as, for example, the brain, lungs, breast, liver, gall bladder, pancreas, prostate gland, and various internal body lumen defined by the esophagus, stomach, intestine, colon, arteries, veins, anus, vagina, cervix, fallopian tubes, and the peritoneal cavity. Minimally invasive electrical ablation devices may be introduced to the tissue treatment region though a small opening formed in the patient's body using a trocar or through a natural body orifice such as the mouth, anus, or vagina using translumenal access techniques known as Natural Orifice Translumenal Endoscopic Surgery (NOTES)™. Once the electrical ablation devices (e.g., electrodes) are located into or proximal to the undesirable tissue in the treatment region, electric field potentials may be applied by the energy source to the undesirable tissue. The electrical ablation devices may comprise portions that may be inserted into the tissue treatment region percutaneously (e.g., where access to inner organs or other tissue is done via needle-puncture of the skin). Other portions of the electrical ablation devices may be introduced into the tissue treatment region endoscopically (e.g., laparoscopically and/or thoracoscopically) through trocars or channels of the endoscope, through small incisions, or transcutaneously (e.g., where electric pulses are delivered to the tissue treatment region through the skin). An electrical ablation device is described in commonly owned U.S. Pat. No. 8,361,066, entitled, ELECTRICAL ABLATION DEVICES, issued Jan. 29, 2013.



FIG. 1 illustrates one embodiment of an electrical ablation system 10. The electrical ablation system 10 may be employed to ablate undesirable tissue, such as, for example, diseased tissue, cancer, malignant and benign tumors, masses, lesions, and other abnormal tissue growths in a tissue treatment region using electrical energy. The electrical ablation system 10 may be configured to treat a number of lesions and ostepathologies comprising metastatic lesions, tumors, fractures, infected sites, and inflamed sites in a tissue treatment region using electrical energy. The electrical ablation system 10 may be configured to be positioned within a patient's natural body orifice, e.g., the mouth, anus, and vagina, and/or advanced through internal body lumen or cavities, e.g., the esophagus, stomach, intestines, colon, cervix, and urethra, to reach the tissue treatment region. The electrical ablation system 10 may be configured to be positioned and passed through a small incision or keyhole formed through the patient's skin or abdominal wall using a trocar to reach the tissue treatment region. The tissue treatment region may be located in the patient's brain, lung, breast, liver, gall bladder, pancreas, prostate gland, various internal body lumen defined by the esophagus, stomach, intestine, colon, arteries, veins, anus, vagina, cervix, fallopian tubes, and the peritoneal cavity. The electrical ablation system 10 may be used in conjunction with endoscopic, laparoscopic, thoracoscopic, open surgical procedures via small incisions or keyholes, percutaneous techniques, transcutaneous techniques, and/or external non-invasive techniques, and any combinations thereof.


Once positioned into or proximate the tissue treatment region, the electrical ablation system 10 may be actuated (e.g., energized) to ablate the undesirable tissue. In one embodiment, the electrical ablation system 10 may be configured to treat diseased tissue in the gastrointestinal tract, esophagus, lung, and/or stomach that may be accessed orally. In another embodiment, the electrical ablation system 10 may be adapted to treat undesirable tissue in the liver or other organs that may be accessible using translumenal access techniques, such as, for example, NOTES™ techniques where the electrical ablation devices may be initially introduced through a natural body orifice and then advanced to the tissue treatment site by puncturing the walls of internal body lumen. In various embodiments, the electrical ablation system 10 may be adapted to treat undesirable tissue in the brain, lung, breast, liver, gall bladder, pancreas, or prostate gland, using one or more electrodes positioned percutaneously, transcutaneously, translumenally, minimally invasively, and/or through open surgical techniques, or any combination thereof.


In one embodiment, the electrical ablation system 10 may be employed in conjunction with a flexible endoscope 12, as well as a rigid endoscope, laparoscope, or thoracoscope, such as the GIF-100 model available from Olympus Corporation. In one embodiment, the endoscope 12 may be introduced to the tissue treatment region trans-anally through the colon, trans-orally through the esophagus and stomach, trans-vaginally through the cervix, transcutaneously, or via an external incision or keyhole formed in the abdomen in conjunction with a trocar. The electrical ablation system 10 may be inserted and guided into or proximate the tissue treatment region using the endoscope 12. In other embodiments, the endoscope 12 is not utilized, and instead other techniques, such as, for example, ultrasound or a computerized tomography (CT) scan, may be used to determine proper instrument placement during the procedure.


In the embodiment illustrated in FIG. 1, the endoscope 12 comprises an endoscope handle 34 and an elongate relatively flexible shaft 32. The distal end of the flexible shaft 32 may comprise a light source and a viewing port. Optionally, the flexible shaft 32 may define one or more channels for receiving various instruments therethrough, such as, for example, electrical ablation devices. Images within the field of view of the viewing port may be received by an optical device, such as, for example, a camera comprising a charge coupled device (CCD) usually located within the endoscope 12, and transmitted to a display monitor (not shown) outside the patient. In one embodiment, the electrical ablation system 10 may comprise a plurality of electrical conductors 18, a handpiece 16 comprising an activation switch 62, and an energy source 14, such as, for example, an electrical waveform generator, electrically coupled to the activation switch 62 and the electrical ablation device 20. The electrical ablation device 20 may comprise a relatively flexible member or shaft 22 that may be introduced to the tissue treatment region using any of the techniques discussed above, such as, an open incision and a trocar, through one of more of the channels of the endoscope 12, percutaneously, or transcutaneously.


In one embodiment, one or more electrodes (e.g., needle electrodes, balloon electrodes), such as first and second electrodes 24a, 24b may extend out from the distal end of the electrical ablation device 20. In one embodiment, the electrical ablation device may comprise multiple needle electrodes that may be employed to treat the undesirable tissue. In one embodiment, the first electrode 24a may be configured as the positive electrode and the second electrode 24b may be configured as the negative electrode. The first electrode 24a may be electrically connected to a first electrical conductor 18a, or similar electrically conductive lead or wire, which may be coupled to the positive terminal of the energy source 14 through the activation switch 62. The second electrode 24b may be electrically connected to a second electrical conductor 18b, or similar electrically conductive lead or wire, which may be coupled to the negative terminal of the energy source 14 through the activation switch 62. The electrical conductors 18a, 18b may be electrically insulated from each other and surrounding structures, except for the electrical connections to the respective electrodes 24a, 24b.


In certain embodiments, the electrical ablation device 20 may be configured to be introduced into or proximate the tissue treatment region using the endoscope 12 (laparoscope or thoracoscope), open surgical procedures, and/or external and non-invasive medical procedures. The electrodes 24a, 24b may be referred to herein as endoscopic or laparoscopic electrodes, although variations thereof may be inserted transcutaneously or percutaneously. In various embodiments, one or both electrodes 24a, 24b may be adapted and configured to slideably move in and out of a cannula, lumen, or channel defined within the flexible shaft 22.


When the electrodes 24a, 24b are positioned at the desired location into or proximate the tissue treatment region, the electrodes 24a, 24b may be connected to or disconnected from the energy source 14 by actuating or de-actuating the activation switch 62 on the handpiece 16. The activation switch 62 may be operated manually or may be mounted on a foot switch (not shown), for example. The electrodes 24a, 24b may deliver electric field pulses to the undesirable tissue. The electric field pulses may be characterized by various parameters, such as, for example, pulse shape, amplitude, frequency, pulse width, polarity, total number of pulses and duration. The electric field pulses may be characterized by amplitudes in the range of ±100 VDC to ±10,000 VDC, pulse widths in the range of 1 μs to 100 ms, and frequencies in the range of 1 Hz to 10,000 Hz. The electric field pulses may be sufficient to induce irreversible electroporation in the undesirable tissue. The induced potential may depend on a variety of conditions, such as, for example, tissue type, cell size, and electric field pulse parameters. The transmembrane potential of a specific tissue type may primarily depend on the amplitude of the electric field and pulse width. Without wishing to be bound to any particular theory, it is believed that an electric field strength of 200 V/cm to 2000 V/cm may be suitable for destroying living tissue by inducing irreversible electroporation. This procedure may be repeated to destroy relatively larger portions of the undesirable tissue. At anytime, the surgeon or clinician may reposition at least one of the electrodes and begin the process anew.


In certain embodiments, a protective sleeve or sheath 26 may be slidably disposed over the flexible shaft 22 and within a handle 28. In another embodiment, the sheath 26 may be slidably disposed within the flexible shaft 22 and the handle 28. The sheath 26 may be slideable and may be located over the electrodes 24a, 24b to protect the trocar and prevent accidental piercing when the electrical ablation device 20 is advanced therethrough. One or both of the electrodes 24a, 24b may be adapted and configured to slideably move in and out of a cannula, lumen, or channel formed within the flexible shaft 22. One or both of the electrodes 24a, 24b may be fixed in place. One of the electrodes 24a, 24b may provide a pivot about which the other electrode may be moved in an arc to other points in the tissue treatment region to treat larger portions of the diseased tissue that cannot be treated by fixing both of the electrodes 24a, 24b in one location. In one embodiment, one or both of the electrodes 24a, 24b may be adapted and configured to slideably move in and out of a working channel formed within a flexible shaft 32 of the endoscope 12 or may be located independently of the endoscope 12.


In one embodiment, the first and second electrical conductors 18a, 18b may be provided through the handle 28. The first electrode 24a may be slideably moved in and out of the distal end of the flexible shaft 22 using a slide member 30 to retract and/or advance the first electrode 24a. The second electrode 24b may be slideably moved in and out of the distal end of the flexible shaft 22 using the slide member 30 or a different slide member to retract and/or advance the second electrode 24b. One or both electrodes 24a, 24b may be coupled to the slide member 30, or additional slide members, to advance and retract the electrodes 24a, 24b and position the electrodes 24a, 24b. In this manner, the first and second electrodes 24a, 24b which may be slidably movable within the cannula, lumen, or channel defined within the flexible shaft 22, may be advanced and retracted with the slide member 30. As shown in FIG. 1, the first electrical conductor 18a coupled to the first electrode 24a may be coupled to the slide member 30. In this manner, the first electrode 24a, which is slidably movable within the cannula, lumen, or channel within the flexible shaft 22, may be advanced and retracted with the slide member 30. In one embodiment, various slide members, such as the slide member 30, may be rotatable. Thus rotation of the slide member 30, or additional slide members, may rotate the corresponding electrode(s) at the distal end of the electrical ablation device 20.


In various other embodiments, transducers and/or sensors 29 may be located in the handle 28 (or other suitable location) of the electrical ablation device 20 to sense the force with which the electrodes 24a, 24b penetrate the tissue in the tissue treatment region. This feedback information may be useful to determine whether one or both of the electrodes 24a, 24b have been properly inserted in the tissue treatment region. As is particularly well known, cancerous tumor tissue tends to be denser than healthy tissue, and thus greater force may be typically required to insert the electrodes 24a, 24b therein. The transducers or sensors 29 may provide feedback to the operator, surgeon, or clinician to physically sense when the electrodes 24a, 24b are placed within the cancerous tumor. The feedback information provided by the transducers or sensors 29 may be processed and displayed by circuits located either internally or externally to the energy source 14. The sensor 29 readings may be employed to determine whether the electrodes 24a, 24b have been properly located within the cancerous tumor thereby assuring that a suitable margin of error has been achieved in locating the electrodes 24a, 24b.


In one embodiment, the input to the energy source 14 may be connected to a commercial power supply by way of a plug (not shown). The output of the energy source 14 may be coupled to the electrodes 24a, 24b, which may be energized using the activation switch 62 on the handpiece 16, or an activation switch mounted on a foot activated pedal (not shown). The energy source 14 may be configured to produce electrical energy suitable for electrical ablation.


In one embodiment, the electrodes 24a, 24b may be adapted and configured to electrically couple to the energy source 14 (e.g., generator, waveform generator). Once electrical energy is coupled to the electrodes 24a, 24b an electric field may be formed at a distal end of the electrodes 24a, 24b. The energy source 14 may be configured to generate electric pulses at a predetermined frequency, amplitude, pulse width, and/or polarity that are suitable to induce irreversible electroporation to ablate substantial volumes of undesirable tissue in the treatment region. For example, the energy source 14 may be configured to deliver DC electric pulses having a predetermined frequency, amplitude, pulse width, and/or polarity suitable to induce irreversible electroporation to ablate substantial volumes of undesirable tissue in the treatment region. The DC pulses may be positive or negative relative to a particular reference polarity. The polarity of the DC pulses may be reversed or inverted from positive-to-negative or negative-to-positive a predetermined number of times to induce irreversible electroporation to ablate substantial volumes of undesirable tissue in the treatment region.


In one embodiment, a timing circuit may be coupled to the output of the energy source 14 to generate electric pulses. The timing circuit may comprise one or more suitable switching elements to produce the electric pulses. For example, the energy source 14 may deliver a series of n electric pulses (where n is any positive integer) to the electrodes 24a, 24b of sufficient amplitude to induce irreversible electroporation suitable for tissue ablation. In one embodiment, the electric pulses may have a fixed or variable pulse width, amplitude, frequency, and/or polarity.


The electrical ablation device 20 may be operated either in bipolar or monopolar mode. In bipolar mode, the first electrode 24a may be electrically connected to a first polarity and the second electrode 24b may be electrically connected to the opposite polarity. In monopolar mode, the first electrode 24a may be coupled to a prescribed voltage and the second electrode 24b may be set to ground. The energy source 14 may be configured to operate in either the bipolar or monopolar modes with the electrical ablation system 10. In bipolar mode, the first electrode 24a may be electrically connected to a prescribed voltage of one polarity and the second electrode 24b may be electrically connected to a prescribed voltage of the opposite polarity. When more than two electrodes are used, the polarity of the electrodes may be alternated so that any two adjacent electrodes may have either the same or opposite polarities.


In monopolar mode, it may not be necessary that the patient be grounded with a grounding pad. Since a monopolar energy source 14 may be typically constructed to operate upon sensing a ground pad connection to the patient, the negative electrode of the energy source 14 may be coupled to an impedance simulation circuit. In this manner, the impedance circuit simulates a connection to the ground pad and thus may be able to activate the energy source 14. It will be appreciated that in monopolar mode, the impedance circuit may be electrically connected in series with either one of the electrodes 24a, 24b that may be otherwise attached to a grounding pad.


In one embodiment, the energy source may be configured to produce RF waveforms at predetermined frequencies, amplitudes, pulse widths, and/or polarities suitable for electrical ablation of cells in the tissue treatment region. One example of a suitable RF energy source may be a commercially available conventional, bipolar/monopolar electrosurgical RF generator, such as Model Number ICC 350, available from Erbe, GmbH.


In one embodiment, the energy source may be configured to produce destabilizing electrical potentials (e.g., fields) suitable to induce irreversible electroporation. The destabilizing electrical potentials may be in the form of bipolar/monopolar DC electric pulses suitable for inducing irreversible electroporation to ablate tissue undesirable tissue with the electrical ablation device. A commercially available energy source suitable for generating irreversible electroporation electric field pulses in bipolar or monopolar mode is a pulsed DC generator such as Model Number ECM 830, available from BTX Molecular Delivery Systems Boston, Mass. In bipolar mode, the first electrode 24a may be electrically coupled to a first polarity and the second electrode 25 may be electrically coupled to a second (e.g., opposite) polarity of the energy source 14. Bipolar/monopolar DC electric pulses may be generated at a variety of frequencies, amplitudes, pulse widths, and/or polarities. Unlike RF ablation systems, which may require high power and energy levels delivered into the tissue to heat and thermally destroy the tissue, irreversible electroporation may require very little energy applied to the tissue to heat and kill the cells of the undesirable tissue using electric field potentials rather than heat. Accordingly, irreversible electroporation systems may avoid the detrimental thermal effects caused by RF ablation systems.


In certain embodiments, the energy source may comprise a wireless transmitter to deliver energy to the electrodes using wireless energy transfer techniques via one or more remotely positioned antennas. Those skilled in the art will appreciate that wireless energy transfer or wireless power transmission refers to the process of transmitting electrical energy from an energy source to an electrical load without interconnecting wires. In one embodiment, the energy source 14 may be coupled to the first and second electrodes 24a, 24b by a wired or a wireless connection. In a wired connection, the energy source 14 may be coupled to the electrodes 24a, 24b by way of the electrical conductors 18a, 18b as shown. In a wireless connection, the electrical conductors 18a, 18b may be replaced with a first antenna (not shown) coupled the energy source 14 and a second antenna (not shown) coupled to the electrodes 24a, 24b, wherein the second antenna may be remotely located from the first antenna. In one embodiment, the energy source may comprise a wireless transmitter to deliver energy to the electrodes using wireless energy transfer techniques via one or more remotely positioned antennas. As previously discussed, wireless energy transfer or wireless power transmission is the process of transmitting electrical energy from the energy source 14 to an electrical load, e.g., the abnormal cells in the tissue treatment region, without using the interconnecting electrical conductors 18a, 18b. An electrical transformer is the simplest example of wireless energy transfer. The primary and secondary circuits of a transformer may not be directly connected and the transfer of energy may take place by electromagnetic coupling through a process known as mutual induction. Power also may be transferred wirelessly using RF energy.


According to certain embodiments, the electrical ablation device 20 may be introduced into the tissue treatment region through a trocar, for example, or inserted to a tissue treatment region transcutaneously, percutaneously, or other suitable techniques. In one embodiment, the cannula, lumen, or channel defined within the flexible shaft 22 may comprise a cutting edge, such as a bevel or other sharp edge, to aid in the puncturing/piercing of tissue.


According to certain embodiments, an ablation apparatus may generally comprise an elongated body having a proximal end and a distal end and a non-conductive tip at the distal end, a conductive sheath at least partially surrounding a portion of the elongated body intermediate the proximal end and the tip, and an electrical conductor electrically connected to the conductive sheath coupled to an energy source operative to generate and deliver a sequence of electrical pulses to tissue to induce cell necrosis in the tissue by irreversible electroporation. Without wishing to be bound to any particular theory, it is believed that the non-conductive tip and/or the conductive sheath may reduce the current density at the tip relative to a similar apparatus having an electrode at the tip. The conductive sheath may delocalize the current density over a greater surface area. The conductive sheath may reduce thermal necrosis at the tip. The non-conductive tip may reduce thermal necrosis at the tip. The conductive sheath and/or non-conductive tip may reduce induced muscle contractions. The ablation apparatus may be operated either in bipolar mode or monopolar mode.


Referring to FIGS. 2A-B, an ablation apparatus 100 may generally comprise an elongated body 105 having a proximal end and a distal end and a non-conductive tip 110 at the distal end, a conductive sheath 120 at least partially surrounding a portion of the elongated body 105 intermediate the proximal end and the tip, and an electrical conductor 130 electrically connected to the conductive sheath 120. The ablation apparatus may comprise an energy source (not shown) coupled to the electrical conductor 130, the energy source configured to deliver a series of electrical pulses to tissue to induce cell necrosis in the tissue by irreversible electroporation. The ablation apparatus 100 may have an elongated body 105 comprising a tapered segment 140. The tapered segment 140 may be intermediate the proximal end and the distal end. The tapered segment 140 may comprise a chamfer cut. The electrical conductor 130 may be positioned in the tapered segment 140. The electrical conductor 130 may be positioned in the chamfer cut. The ablation apparatus 100 may have an elongated body 105 comprising a tapered tip 110. The tip 110 may comprise a bevel cut. The tip 110 may comprise a cutting edge. In one embodiment, an ablation apparatus 100 may generally comprise an elongated body 105 comprising a tapered segment 140 having a chamfer cut including an electrical conductor 130 therein, and a tapered tip 110 having a bevel cut.


In certain embodiments, the non-conductive tip 110 may comprise a ceramic material, a polymer, a glass material, a carbon material, and any combinations thereof. In one embodiment, the non-conductive tip 110 may comprise polyalkenes, such as polyethylene and polypropylene, silicon, and polytetrafluoroethylene, such as TEFLON. The non-conductive tip may comprise a substantial portion of the distal end of the elongated body. The non-conductive tip may have an area less than the area of the conductive sheath. The area of the non-conductive tip may be 50%, 75%, or 90% less than the area of the conductive sheath.


In certain embodiments, the conductive sheath 120 may comprise a metal. In one embodiment, the conductive sheath 120 may comprise a metal selected from the group consisting of medical grade stainless steel, gold, platinum, and iridium. The conductive sheath may have a length, width, diameter, and thickness. In various embodiments, for example, the conductive sheath may have a length of 5 cm to 25 cm, a width or diameter of 0.5 mm to 1 mm, and a thickness of 0.5 mm to 1 mm. The conductive sheath may have any suitable shape, such as, for example, cylinder and cube. The conductive sheath may be deposited onto at least a portion of the ablation apparatus. The conductive sheath may be deposited onto at least a portion of a circumferential surface of the ablation apparatus. The conductive sheath may be deposited onto at least a portion of a circumferential surface of the ablation apparatus intermediate the proximal end and the tip. The conductive sheath may surround the tapered segment of the elongated body. The conductive sheath may surround the chamfer cut of the elongated body. The electrical conductor 130 may be fixedly attached to the conductive sheath 120.


According to certain embodiments, an ablation apparatus may generally comprise a first electrode, a plurality of second electrodes, a grounding pad, and an energy source coupled to the first electrode and plurality of second electrodes, the energy source configured to deliver a series of electrical pulses to tissue to induce cell necrosis in the tissue by irreversible electroporation. The first electrode may be connected to the positive output of the generator, the plurality of second electrodes may be connected to the negative output of the generator, and the grounding pad may be connected to the negative output of the generator. In one embodiment, the ground pad may be replaced by an impedance simulation circuit. The polarity of the plurality of second electrodes and the polarity of the grounding pad may be the same. Without wishing to be bound to any particular theory, it is believed having the same polarity may reduce the current density at the electrode tips relative to a similar ablation apparatus having a different polarity. The grounding pad may delocalize the current density over a greater surface area. The grounding pad may reduce thermal necrosis at the tip. The grounding pad may reduce induced muscle contractions.


In certain embodiments, the first electrode may have a first diameter and each of the plurality of second electrodes may have a second diameter. The first diameter may be greater than or equal to the second diameter. The first diameter may be greater than the second diameter. For example, the first diameter may be 18 gage and the second diameter may be 25 gage. Without wishing to be bound to any particular theory, it is believed that the smaller diameter of the plurality of second electrodes may reduce the current density at the tip relative to a similar electrode having a larger diameter. For example, the smaller diameter may divide the current into smaller amounts flowing from the multiple second electrodes. The current flowing from the first electrode generally equals the sum of the current flowing to the second electrodes when the electrodes are electrically connected. The smaller diameter may reduce thermal necrosis at the electrode tip. The smaller diameter may reduce induced muscle contractions.


Referring to FIGS. 3 and 4, in certain embodiments, an ablation apparatus may generally comprise a first electrode 310 having a first diameter, a plurality of second electrodes 320 each having a second diameter comprising a proximal end and a distal end and a first conductive portion 312 intermediate the proximal end and the distal end, a non-conductive portion 314 intermediate the first conductive portion 312 and the distal end, and a second conductive portion 316 at the distal end, a grounding pad 330 comprising a non-conductive outer region 332 and a conductive inner region 334, and an energy source (not shown) coupled to the first electrode 310 and plurality of second electrodes 320, the energy source configured to deliver a series of electrical pulses to tissue 350 to induce cell necrosis 360 in the tissue 350 by irreversible electroporation, wherein the first diameter is greater than or equal to the second diameter. The ground pad may comprise a central hole 340. In one embodiment, the first electrode 310 may be positioned in the central hole 340 and the plurality of second electrodes 320 may be randomly positioned around the central hole 340. The plurality of second electrodes may comprise 1-10 electrodes and 2-8 electrodes, such as, for example, 2 electrodes, 4 electrodes, and 6 electrodes.


In certain embodiments, the grounding pad 330 may comprise a non-conductive outer region 332 and a conductive inner region 334. The first electrode 310 may contact the non-conductive outer region 332. The first electrode 310 may not contact the conductive inner region 334. Each of the plurality of second electrodes 320 may contact the non-conductive outer region 332 and the conductive inner region 334. The first conductive portion 312 of each of the plurality of second electrodes 320 may contact the conductive inner region 334. The second conductive portion 316 of each of the plurality of second electrodes 320 may contact the tissue 350. The non-conductive portion 314 of each of the plurality of second electrodes 320 may contact the patient's abdominal wall.


According to certain embodiments, an ablation apparatus may generally comprise a first electrode 310 contacting the tissue 350 at a first distance and each of the plurality of second electrodes 320 contacting the tissue at a second distance. In one embodiment, the first electrode 310 may be positioned in the central hole 340 and advanced into the tissue 350 under ultrasound guidance a first distance, and the plurality of second electrodes 320 may be randomly positioned around the central hole 340 and advanced into the tissue 350 without ultrasound guidance a second distance. In one embodiment, the first distance may be greater than or equal to the second distance. In various embodiments, the distance between the electrodes may be from 0.5 cm to 15 cm. The plurality of second electrodes 320 may be positioned around and/or above bone and other solid structures. For example, the first electrode may be positioned in the liver a first distance suitable to create a zone of cell necrosis 360 and the second electrodes may be positioned in the liver around ribs at a second distance, such as, for example, 1-2 cm. The treatment of the patient may be more efficient without the need to place all electrodes under ultrasound guidance and/or the need to position all electrodes at the same distance.


According to certain embodiments, a method of treating tissue of a patient may generally comprise positioning a grounding pad adjacent the patient, inserting a first electrode under ultrasound guidance into the tissue to a first distance, inserting a plurality of second electrodes into the tissue to a second distance, and delivering a series of electrical pulses to tissue to induce cell necrosis in the tissue by irreversible electroporation. The method may comprise inserting a first electrode under ultrasound guidance through the central hole and into the tissue. The method may comprise inserting a plurality of second electrodes through the grounding pad into the tissue. The plurality of second electrodes may be inserted without ultrasound guidance. The method may comprise contacting the first conductive portion of each of the second electrodes and the conductive inner region of the grounding pad. The method may comprise conducting energy from the first electrode to each of the plurality of second electrodes and the conductive inner region of the grounding pad. The first electrode may have a first polarity and the grounding pad and the plurality of second electrodes may have a different polarity. The polarity of the grounding pad and the polarity of the plurality of second electrodes may be the same.



FIGS. 5 and 6 illustrate a finite element model of the electric field created in the undesirable tissue when the electrodes are energized. As shown in FIGS. 5 and 6, the horizontal and the vertical axes represent distance in meters (m) with the center defined at by the location of the first electrode located directly in the undesirable tissue. A vertical scale shown to the right of the graph represents the electric field strength in a range from a minimum of about 500 V/m (bottom) to a maximum of about 5500 V/m (top). Wth the electrodes positioned as described in FIG. 4, when the DC pulses are applied to the first electrode 410 located directly in the undesirable tissue a necrotic zone 460 may be created around the first electrode 410. Although a small amount of necrosis 462 may occurs at the second electrode/tissue interface 416, it will likely not be a clinically significant amount. Irreversible electroporation energy in the range of 200 V/cm to 1500 V/cm is generally suitable for efficient and effective treatment of medical conditions that require the ablation of undesirable tissue from a localized region.


The embodiments of the electrical ablation devices described herein may be introduced inside a patient using minimally invasive or open surgical techniques. In some instances it may be advantageous to introduce the electrical ablation devices inside the patient using a combination of minimally invasive and open surgical techniques. Minimally invasive techniques may provide more accurate and effective access to the treatment region for diagnostic and treatment procedures. To reach internal treatment regions within the patient, the electrical ablation devices described herein may be inserted through natural openings of the body such as the mouth, anus, and/or vagina, for example. Minimally invasive procedures performed by the introduction of various medical devices into the patient through a natural opening of the patient are known in the art as NOTES™ procedures. Surgical devices, such as an electrical ablation devices, may be introduced to the treatment region through the channels of the endoscope to perform key surgical activities (KSA), including, for example, electrical ablation of tissues using irreversible electroporation energy. Some portions of the electrical ablation devices may be introduced to the tissue treatment region percutaneously or through small-keyhole-incisions.


Endoscopic minimally invasive surgical and diagnostic medical procedures are used to evaluate and treat internal organs by inserting a small tube into the body. The endoscope may have a rigid or a flexible tube. A flexible endoscope may be introduced either through a natural body opening (e.g., mouth, anus, and/or vagina). A rigid endoscope may be introduced via trocar through a relatively small-keyhole-incision incisions (usually 0.5-1.5 cm). The endoscope can be used to observe surface conditions of internal organs, including abnormal or diseased tissue such as lesions and other surface conditions and capture images for visual inspection and photography. The endoscope may be adapted and configured with channels for introducing medical instruments to the treatment region for taking biopsies, retrieving foreign objects, and/or performing surgical procedures.


Once an electrical ablation device is inserted in the human body internal organs may be reached using trans-organ or translumenal surgical procedures. The electrical ablation device may be advanced to the treatment site using endoscopic translumenal access techniques to perforate a lumen, and then, advance the electrical ablation device and the endoscope into the peritoneal cavity. Translumenal access procedures for perforating a lumen wall, inserting, and advancing an endoscope therethrough, and pneumoperitoneum devices for insufflating the peritoneal cavity and closing or suturing the perforated lumen wall are well known. During a translumenal access procedure, a puncture must be formed in the stomach wall or in the gastrointestinal tract to access the peritoneal cavity. One device often used to form such a puncture is a needle knife which is inserted through the channel of the endoscope, and which utilizes energy to penetrate through the tissue. A guidewire is then feed through the endoscope and is passed through the puncture in the stomach wall and into the peritoneal cavity. The needle knife is removed, leaving the guidewire as a placeholder. A balloon catheter is then passed over the guidewire and through the channel of the endoscope to position the balloon within the opening in the stomach wall. The balloon can then be inflated to increase the size of the opening, thereby enabling the endoscope to push against the rear of the balloon and to be feed through the opening and into the peritoneal cavity. Once the endoscope is positioned within the peritoneal cavity, numerous procedures can be performed through the channel of the endoscope.


The endoscope may be connected to a video camera (single chip or multiple chips) and may be attached to a fiber-optic cable system connected to a “cold” light source (halogen or xenon), to illuminate the operative field. The video camera provides a direct line-of-sight view of the treatment region. If working in the abdomen, the abdomen may be insufflated with carbon dioxide (CO2) gas to create a working and viewing space. The abdomen is essentially blown up like a balloon (insufflated), elevating the abdominal wall above the internal organs like a dome. CO2 gas is used because it is common to the human body and can be removed by the respiratory system if it is absorbed through tissue.


Once the electrical ablation devices are located at the target site, the diseased tissue may be electrically ablated or destroyed using the various embodiments of electrodes discussed herein. The placement and location of the electrodes can be important for effective and efficient electrical ablation therapy. For example, the electrodes may be positioned proximal to a treatment region (e.g., target site or worksite) either endoscopically or transcutaneously (percutaneously). In some implementations, it may be necessary to introduce the electrodes inside the patient using a combination of endoscopic, transcutaneous, and/or open techniques. The electrodes may be introduced to the tissue treatment region through a channel of the endoscope, an overtube, or a trocar and, in some implementations, may be introduced through percutaneously or through small-keyhole-incisions.


Preferably, the various embodiments of the devices described herein will be processed before surgery. First, a new or used instrument is obtained and if necessary cleaned. The instrument can then be sterilized. In one sterilization technique, the instrument is placed in a closed and sealed container, such as a plastic or TYVEK® bag. The container and instrument are then placed in a field of radiation that can penetrate the container, such as gamma radiation, x-rays, or high-energy electrons. The radiation kills bacteria on the instrument and in the container. The sterilized instrument can then be stored in the sterile container. The sealed container keeps the instrument sterile until it is opened in the medical facility.


It is preferred that the device is sterilized prior to use. This can be done by any number of ways known to those skilled in the art including beta or gamma radiation, ethylene oxide, steam.


Although the various embodiments of the devices have been described herein in connection with certain disclosed embodiments, many modifications and variations to those embodiments may be implemented. For example, different types of end effectors may be employed. Also, where materials are disclosed for certain components, other materials may be used. The foregoing description and following claims are intended to cover all such modification and variations.


Any patent, publication, or other disclosure material, in whole or in part, that is said to be incorporated by reference herein is incorporated herein only to the extent that the incorporated materials does not conflict with existing definitions, statements, or other disclosure material set forth in this disclosure. As such, and to the extent necessary, the disclosure as explicitly set forth herein supersedes any conflicting material incorporated herein by reference. Any material, or portion thereof, that is said to be incorporated by reference herein, but which conflicts with existing definitions, statements, or other disclosure material set forth herein will only be incorporated to the extent that no conflict arises between that incorporated material and the existing disclosure material.

Claims
  • 1. An ablation apparatus, comprising: a first electrode having a first diameter;a plurality of second electrodes, each of the plurality of second electrodes having a second diameter, and wherein each of the plurality of second electrodes comprises: a proximal end;a distal end;a first conductive portion intermediate the proximal end and the distal end;a non-conductive portion intermediate the first conductive portion and the distal end; anda second conductive portion at the distal end;a grounding pad comprising a non-conductive outer region and a conductive inner region, wherein the grounding pad further defines a hole, and wherein the first electrode is positioned within the hole; andan energy source coupled to the first electrode and the plurality of second electrodes, wherein the energy source is configured to deliver a series of electrical pulses to tissue to induce cell necrosis by irreversible electroporation; andwherein the first diameter is greater than the second diameter.
  • 2. An ablation apparatus, comprising: a first electrode having a first diameter;a plurality of second electrodes, each of the plurality of second electrodes having a second diameter, and wherein each of the plurality of second electrodes comprises: a proximal end;a distal end;a first conductive portion intermediate the proximal end and the distal end;a non-conductive portion intermediate the first conductive portion and the distal end; anda second conductive portion at the distal end;a grounding pad comprising a non-conductive outer region and a conductive inner region, wherein the first electrode does not contact the conductive inner region of the grounding pad; andan energy source coupled to the first electrode and the plurality of second electrodes, wherein the energy source is configured to deliver a series of electrical pulses to tissue to induce cell necrosis by irreversible electroporation; andwherein the first diameter is greater than the second diameter.
  • 3. The ablation apparatus of claim 2, wherein the first conductive portion of each of the plurality of second electrodes is positioned in contact with the conductive inner region of the grounding pad.
  • 4. The ablation apparatus of claim 3, wherein the first electrode is advanced into the tissue a first distance, wherein each of the plurality of second electrodes is advanced into the tissue a second distance, and wherein the first distance is greater than the second distance.
  • 5. The ablation apparatus of claim 2, wherein the series of electrical pulses are characterized by amplitudes in a range of about ±100 VDC to about ±10,000 VDC, pulse widths in a range of about 1 μs to about 100 ms, and frequencies in a range of about 1 Hz to about 10,000 Hz.
  • 6. The ablation apparatus of claim 2, wherein the ablation apparatus is electrically monopolar.
  • 7. An ablation apparatus, comprising: a first electrode;a plurality of second electrodes, wherein each second electrode comprises: a proximal end;a distal end;a first conductive portion intermediate the proximal end and the distal end;a non-conductive portion intermediate the first conductive portion and the distal end; anda second conductive portion at the distal end;a grounding pad, wherein the grounding pad defines a hole, and wherein the first electrode is configured for insertion through the hole; andan energy source electrically coupled to the first electrode and the plurality of second electrodes, wherein the energy source is configured to deliver a series of electrical pulses to tissue to induce cell necrosis by irreversible electroporation.
  • 8. The ablation apparatus of claim 7, wherein the first electrode comprises a first diameter, wherein each second electrode comprises a second diameter, and wherein the first diameter is greater than or equal to the second diameter.
  • 9. The ablation apparatus of claim 7, wherein the first electrode is configured for advancement into the tissue to a first distance, and wherein each second electrode is configured for advancement into the tissue to a second distance.
  • 10. The ablation apparatus of claim 9, wherein the first distance is greater than or equal to the second distance, and wherein the first distance is suitable to create a necrotic zone.
  • 11. The ablation apparatus of claim 9, wherein the first electrode is configured for advancement into the tissue to the first distance under ultrasound guidance.
  • 12. An ablation apparatus, comprising: a first electrode;a plurality of second electrodes, wherein each second electrode comprises: a proximal end;a distal end;a first conductive portion intermediate the proximal end and the distal end;a non-conductive portion intermediate the first conductive portion and the distal end; anda second conductive portion at the distal end;a grounding pad, wherein the grounding pad comprises a non-conductive outer region, a conductive inner region, and defines a hole; andan energy source electrically coupled to the first electrode and the plurality of second electrodes, wherein the energy source is configured to deliver a series of electrical pulses to tissue to induce cell necrosis by irreversible electroporation.
  • 13. The ablation apparatus of claim 12, wherein each second electrode is positioned around the hole of the grounding pad.
  • 14. The ablation apparatus of claim 12, wherein each second electrode is positioned around the hole of the grounding pad and above or around one or more bones.
  • 15. The ablation apparatus of claim 12, wherein the first electrode is configured for insertion through the hole and into the tissue to a first distance, and wherein each second electrode is configured for insertion through the grounding pad and into the tissue to a second distance.
  • 16. The ablation apparatus of claim 15, wherein the first conductive portion of each second electrode is positioned in contact with the conductive inner region of the grounding pad, and wherein the non-conductive portion of each second electrode is positioned in contact with the non-conductive outer region of the grounding pad.
  • 17. An ablation device for coupling to an energy source delivering a series of electrical pulses to tissue to induce cell necrosis by irreversible electroporation, wherein the ablation device comprises: a first electrode coupleable to the energy source;a plurality of second electrodes, wherein each second electrode is coupleable to the energy source, and wherein each second electrode comprises: a first conductive section;a second conductive section; anda non-conductive section between the first conductive section and the second conductive section; anda grounding pad, wherein the grounding pad defines a hole, and wherein the first electrode is insertable through the hole.
  • 18. The ablation device of claim 17, wherein the first electrode comprises a first diameter and each second electrode comprises a second diameter.
  • 19. The ablation device of claim 17, wherein the grounding pad comprises a non-conductive outer region and a conductive inner region, wherein the first conductive section of each second electrode is positioned in contact with the conductive inner region, wherein the non-conductive section of each second electrode is positioned in contact with the non-conductive outer region, and wherein the second conductive section of each second electrode is configured for advancement into tissue.
  • 20. An ablation device for coupling to an energy source delivering a series of electrical pulses to tissue to induce cell necrosis by irreversible electroporation, wherein the ablation device comprises: a first electrode coupleable to the energy source;a plurality of second electrodes, wherein each second electrode is coupleable to the energy source, and wherein each second electrode comprises: a first conductive section;a second conductive section; anda non-conductive section between the first conductive section and the second conductive section; anda grounding pad, wherein the grounding pad defines a hole, and wherein the first electrode is configured for insertion through the hole and into tissue to a first distance, and wherein each second electrode is configured for insertion through the grounding pad and into the tissue to a second distance.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a divisional application claiming priority under 35 U.S.C. § 121 to U.S. patent application Ser. No. 13/036,895, now U.S. Pat. No. 9,254,169, filed Feb. 28, 2011, entitled ELECTRICAL ABLATION DEVICES AND METHODS, the entire disclosure of which is hereby incorporated by reference herein.

US Referenced Citations (1904)
Number Name Date Kind
112794 Felton Mar 1871 A
645576 Tesla Mar 1900 A
649621 Tesla May 1900 A
787412 Tesla Apr 1905 A
1039354 Bonadio Sep 1912 A
1127948 Wappler Feb 1915 A
1482653 Lilly Feb 1924 A
1581706 White Apr 1926 A
1581707 White Apr 1926 A
1581708 White Apr 1926 A
1581709 White Apr 1926 A
1581710 White Apr 1926 A
1625602 Gould Apr 1927 A
1916722 Ende Jul 1933 A
2028635 Wappler Jan 1936 A
2031682 Wappler Feb 1936 A
2113246 Wappler Apr 1938 A
2137710 Anderson Nov 1938 A
2155365 Rankin Apr 1939 A
2191858 Moore Feb 1940 A
2196620 Attarian Apr 1940 A
2388137 Graumlich Oct 1945 A
2451077 Emsig Oct 1948 A
2493108 Casey Jan 1950 A
2504152 Riker Apr 1950 A
2938382 De Graaf May 1960 A
2952206 Becksted Sep 1960 A
3044461 Murdock Jul 1962 A
3069195 Buck Dec 1962 A
3070088 Brahos Dec 1962 A
3110956 Fischer, Jr. Nov 1963 A
3170471 Schnitzer Feb 1965 A
3435824 Gamponia Apr 1969 A
3470876 Barchilon Oct 1969 A
3481325 Glassman Dec 1969 A
3595239 Petersen Jul 1971 A
3669487 Roberts et al. Jun 1972 A
3746881 Fitch et al. Jul 1973 A
3799672 Vurek Mar 1974 A
3854473 Matsuo Dec 1974 A
3854743 Hansen Dec 1974 A
3929123 Jamshidi Dec 1975 A
3946740 Bassett Mar 1976 A
3948251 Hosono Apr 1976 A
3961632 Moossun Jun 1976 A
3965890 Gauthier Jun 1976 A
3994301 Agris Nov 1976 A
4011872 Komiya Mar 1977 A
4012812 Black Mar 1977 A
4043342 Morrison, Jr. Aug 1977 A
4071028 Perkins Jan 1978 A
4085743 Yoon Apr 1978 A
4164225 Johnson et al. Aug 1979 A
4170997 Pinnow et al. Oct 1979 A
4174715 Hasson Nov 1979 A
4178920 Cawood, Jr. et al. Dec 1979 A
4207873 Kruy Jun 1980 A
4235238 Ogiu et al. Nov 1980 A
4258716 Sutherland Mar 1981 A
4269174 Adair May 1981 A
4278077 Mizumoto Jul 1981 A
4281646 Kinoshita Aug 1981 A
4285344 Marshall Aug 1981 A
4311143 Komiya Jan 1982 A
4329980 Terada May 1982 A
4393872 Reznik et al. Jul 1983 A
4396021 Baumgartner Aug 1983 A
4396139 Hall et al. Aug 1983 A
4406656 Hattler et al. Sep 1983 A
4452246 Bader et al. Jun 1984 A
4461281 Carson Jul 1984 A
4491132 Aikins Jan 1985 A
4492232 Green Jan 1985 A
4527331 Lasner et al. Jul 1985 A
4527564 Eguchi et al. Jul 1985 A
4538594 Boebel et al. Sep 1985 A
D281104 Davison Oct 1985 S
4569347 Frisbie Feb 1986 A
4580551 Siegmund et al. Apr 1986 A
4646722 Silverstein et al. Mar 1987 A
4649904 Krauter et al. Mar 1987 A
4653476 Bonnet Mar 1987 A
4655219 Petruzzi Apr 1987 A
4657016 Garito et al. Apr 1987 A
4657018 Hakky Apr 1987 A
4669470 Brandfield Jun 1987 A
4671477 Cullen Jun 1987 A
4677982 Llinas et al. Jul 1987 A
4685447 Iversen et al. Aug 1987 A
4711239 Sorochenko et al. Dec 1987 A
4711240 Goldwasser et al. Dec 1987 A
4712545 Honkanen Dec 1987 A
4721116 Schintgen et al. Jan 1988 A
4727600 Avakian Feb 1988 A
4733662 DeSatnick et al. Mar 1988 A
D295894 Sharkany et al. May 1988 S
4742817 Kawashima et al. May 1988 A
4753223 Bremer Jun 1988 A
4763669 Jaeger Aug 1988 A
4770188 Chikama Sep 1988 A
4790624 Van Hoye et al. Dec 1988 A
4791707 Tucker Dec 1988 A
4796627 Tucker Jan 1989 A
4807593 Ito Feb 1989 A
4815450 Patel Mar 1989 A
4819620 Okutsu Apr 1989 A
4823794 Pierce Apr 1989 A
4829999 Auth May 1989 A
4836188 Berry Jun 1989 A
4846573 Taylor et al. Jul 1989 A
4867140 Hovis et al. Sep 1989 A
4869238 Opie et al. Sep 1989 A
4869459 Bourne Sep 1989 A
4873979 Hanna Oct 1989 A
4880015 Nierman Nov 1989 A
4904048 Sogawa et al. Feb 1990 A
4911148 Sosnowski et al. Mar 1990 A
4926860 Stice et al. May 1990 A
4934364 Green Jun 1990 A
4938214 Specht et al. Jul 1990 A
4950273 Briggs Aug 1990 A
4950285 Wilk Aug 1990 A
4953539 Nakamura et al. Sep 1990 A
4960133 Hewson Oct 1990 A
4977887 Gouda Dec 1990 A
4979496 Komi Dec 1990 A
4979950 Transue et al. Dec 1990 A
4984581 Stice Jan 1991 A
4990152 Yoon Feb 1991 A
4991565 Takahashi et al. Feb 1991 A
4994079 Genese et al. Feb 1991 A
5007917 Evans Apr 1991 A
5010876 Henley et al. Apr 1991 A
5015249 Nakao et al. May 1991 A
5020514 Heckele Jun 1991 A
5020535 Parker et al. Jun 1991 A
5025778 Silverstein et al. Jun 1991 A
5026379 Yoon Jun 1991 A
5033169 Bindon Jul 1991 A
5037433 Wilk et al. Aug 1991 A
5041129 Hayhurst et al. Aug 1991 A
5046513 Gatturna et al. Sep 1991 A
5049153 Nakao et al. Sep 1991 A
5050585 Takahashi Sep 1991 A
5052372 Shapiro Oct 1991 A
5065516 Dulebohn Nov 1991 A
5066295 Kozak et al. Nov 1991 A
5098378 Piontek et al. Mar 1992 A
5099827 Melzer et al. Mar 1992 A
5108421 Fowler Apr 1992 A
5123913 Wilk et al. Jun 1992 A
5123914 Cope Jun 1992 A
5133727 Bales et al. Jul 1992 A
5147374 Fernandez Sep 1992 A
5156609 Nakao et al. Oct 1992 A
5174300 Bales et al. Dec 1992 A
5176126 Chikama Jan 1993 A
5190050 Nitzsche Mar 1993 A
5190555 Wetter et al. Mar 1993 A
5192284 Pleatman Mar 1993 A
5192300 Fowler Mar 1993 A
5197963 Parins Mar 1993 A
5201752 Brown et al. Apr 1993 A
5201908 Jones Apr 1993 A
5203785 Slater Apr 1993 A
5203787 Noblitt et al. Apr 1993 A
5209747 Knoepfler May 1993 A
5217003 Wilk Jun 1993 A
5217453 Wilk Jun 1993 A
5219357 Honkanen et al. Jun 1993 A
5219358 Bendel et al. Jun 1993 A
5222362 Maus et al. Jun 1993 A
5222961 Nakao et al. Jun 1993 A
5222965 Haughton Jun 1993 A
5234437 Sepetka Aug 1993 A
5234453 Smith et al. Aug 1993 A
5235964 Abenaim Aug 1993 A
5242456 Nash et al. Sep 1993 A
5245460 Allen et al. Sep 1993 A
5246424 Wilk Sep 1993 A
5257999 Slanetz, Jr. Nov 1993 A
5259366 Reydel et al. Nov 1993 A
5263958 deGuillebon et al. Nov 1993 A
5273524 Fox et al. Dec 1993 A
5275607 Lo et al. Jan 1994 A
5275614 Haber et al. Jan 1994 A
5275616 Fowler Jan 1994 A
5284128 Hart Feb 1994 A
5284162 Wilk Feb 1994 A
5287845 Faul et al. Feb 1994 A
5287852 Arkinstall Feb 1994 A
5290299 Fain et al. Mar 1994 A
5290302 Pericic Mar 1994 A
5295977 Cohen et al. Mar 1994 A
5297536 Wilk Mar 1994 A
5297687 Freed Mar 1994 A
5301061 Nakada et al. Apr 1994 A
5312023 Green et al. May 1994 A
5312333 Churinetz et al. May 1994 A
5312351 Gerrone May 1994 A
5312416 Spaeth et al. May 1994 A
5312423 Rosenbluth et al. May 1994 A
5318589 Lichtman Jun 1994 A
5320636 Slater Jun 1994 A
5324261 Amundson et al. Jun 1994 A
5325845 Adair Jul 1994 A
5330471 Eggers Jul 1994 A
5330486 Wilk Jul 1994 A
5330488 Goldrath Jul 1994 A
5330496 Alferness Jul 1994 A
5330502 Hassler et al. Jul 1994 A
5331971 Bales et al. Jul 1994 A
5334168 Hemmer Aug 1994 A
5334198 Hart et al. Aug 1994 A
5336192 Palestrant Aug 1994 A
5336222 Durgin, Jr. et al. Aug 1994 A
5339805 Parker Aug 1994 A
5341815 Cofone et al. Aug 1994 A
5342396 Cook Aug 1994 A
5344428 Griffiths Sep 1994 A
5345927 Bonutti Sep 1994 A
5348259 Blanco et al. Sep 1994 A
5350391 Iacovelli Sep 1994 A
5352184 Goldberg et al. Oct 1994 A
5352222 Rydell Oct 1994 A
5354302 Ko Oct 1994 A
5354311 Kambin et al. Oct 1994 A
5356381 Ensminger et al. Oct 1994 A
5356408 Rydell Oct 1994 A
5360428 Hutchinson, Jr. Nov 1994 A
5364408 Gordon Nov 1994 A
5364410 Failla et al. Nov 1994 A
5366466 Christian et al. Nov 1994 A
5366467 Lynch et al. Nov 1994 A
5368605 Miller, Jr. Nov 1994 A
5368606 Marlow et al. Nov 1994 A
5370647 Graber et al. Dec 1994 A
5370679 Atlee, III Dec 1994 A
5374273 Nakao et al. Dec 1994 A
5374275 Bradley et al. Dec 1994 A
5374277 Hassler Dec 1994 A
5374953 Sasaki et al. Dec 1994 A
5376077 Gomringer Dec 1994 A
5377695 An Haack Jan 1995 A
5378234 Hammerslag et al. Jan 1995 A
5383877 Clarke Jan 1995 A
5383888 Zvenyatsky et al. Jan 1995 A
5386817 Jones Feb 1995 A
5387259 Davidson Feb 1995 A
5391174 Weston Feb 1995 A
5392789 Slater et al. Feb 1995 A
5395367 Wilk Mar 1995 A
5395381 Green et al. Mar 1995 A
5395386 Slater Mar 1995 A
5397332 Kammerer et al. Mar 1995 A
5401248 Bencini Mar 1995 A
5403311 Abele Apr 1995 A
5403326 Harrison et al. Apr 1995 A
5403328 Shallman Apr 1995 A
5403342 Tovey et al. Apr 1995 A
5403348 Bonutti Apr 1995 A
5405073 Porter Apr 1995 A
5405359 Pierce Apr 1995 A
5409478 Gerry et al. Apr 1995 A
5417699 Klein et al. May 1995 A
5423821 Pasque Jun 1995 A
5431635 Yoon Jul 1995 A
5433721 Hooven et al. Jul 1995 A
5433735 Zanakis et al. Jul 1995 A
5439471 Kerr Aug 1995 A
5439478 Palmer Aug 1995 A
5441059 Dannan Aug 1995 A
5441494 Ortiz Aug 1995 A
5441498 Perkins Aug 1995 A
5441499 Fritzsch Aug 1995 A
5443463 Stern et al. Aug 1995 A
5445638 Rydell et al. Aug 1995 A
5445648 Cook Aug 1995 A
5449021 Chikama Sep 1995 A
5454827 Aust et al. Oct 1995 A
5456667 Ham et al. Oct 1995 A
5456684 Schmidt et al. Oct 1995 A
5458131 Wilk Oct 1995 A
5458583 McNeely et al. Oct 1995 A
5460168 Masubuchi et al. Oct 1995 A
5460629 Shlain et al. Oct 1995 A
5462561 Voda Oct 1995 A
5465731 Bell et al. Nov 1995 A
5467763 McMahon et al. Nov 1995 A
5468250 Paraschac et al. Nov 1995 A
5470308 Edwards et al. Nov 1995 A
5470320 Tiefenbrun et al. Nov 1995 A
5472441 Edwards et al. Dec 1995 A
5478347 Aranyi Dec 1995 A
5478352 Fowler Dec 1995 A
5480404 Kammerer et al. Jan 1996 A
5482029 Sekiguchi et al. Jan 1996 A
5482054 Slater et al. Jan 1996 A
5484451 Akopov et al. Jan 1996 A
5489256 Adair Feb 1996 A
5496347 Hashiguchi et al. Mar 1996 A
5499990 Schulken et al. Mar 1996 A
5499992 Meade et al. Mar 1996 A
5499997 Sharpe et al. Mar 1996 A
5500012 Brucker et al. Mar 1996 A
5501692 Riza Mar 1996 A
5503616 Jones Apr 1996 A
5505686 Willis et al. Apr 1996 A
5507755 Gresl et al. Apr 1996 A
5511564 Wilk Apr 1996 A
5514157 Nicholas et al. May 1996 A
5518501 Oneda et al. May 1996 A
5522829 Michalos Jun 1996 A
5522830 Aranyi Jun 1996 A
5527321 Hinchliffe Jun 1996 A
5533418 Wu et al. Jul 1996 A
5536234 Newman Jul 1996 A
5536248 Weaver et al. Jul 1996 A
5538509 Dunlap et al. Jul 1996 A
5540648 Yoon Jul 1996 A
5549637 Crainich Aug 1996 A
5554151 Hinchliffe Sep 1996 A
5555883 Avitall Sep 1996 A
5558133 Bortoli et al. Sep 1996 A
5562693 Devlin et al. Oct 1996 A
5569243 Kortenbach et al. Oct 1996 A
5569298 Schnell Oct 1996 A
5571090 Sherts Nov 1996 A
5573540 Yoon Nov 1996 A
5578030 Levin Nov 1996 A
5582611 Tsuruta et al. Dec 1996 A
5582617 Klieman et al. Dec 1996 A
5584845 Hart Dec 1996 A
5590660 MacAulay et al. Jan 1997 A
5591179 Edelstein Jan 1997 A
5591205 Fowler Jan 1997 A
5593420 Eubanks, Jr. et al. Jan 1997 A
5595562 Grier Jan 1997 A
5597378 Jervis Jan 1997 A
5601573 Fogelberg et al. Feb 1997 A
5601574 Stefanchik et al. Feb 1997 A
5601588 Tonomura et al. Feb 1997 A
5601602 Fowler Feb 1997 A
5604531 Iddan et al. Feb 1997 A
5607386 Flam Mar 1997 A
5607389 Edwards et al. Mar 1997 A
5607406 Hernandez et al. Mar 1997 A
5607450 Zvenyatsky et al. Mar 1997 A
5609601 Kolesa et al. Mar 1997 A
5613975 Christy Mar 1997 A
5613977 Weber et al. Mar 1997 A
5614943 Nakamura et al. Mar 1997 A
5616117 Dinkier et al. Apr 1997 A
5618303 Marlow et al. Apr 1997 A
5620415 Lucey et al. Apr 1997 A
5624399 Ackerman Apr 1997 A
5624431 Gerry et al. Apr 1997 A
5626578 Tihon May 1997 A
5626587 Bishop et al. May 1997 A
5628732 Antoon, Jr. et al. May 1997 A
5630782 Adair May 1997 A
5630795 Kuramoto et al. May 1997 A
5643283 Younker Jul 1997 A
5643292 Hart Jul 1997 A
5643294 Tovey et al. Jul 1997 A
5644798 Shah Jul 1997 A
5645083 Essig et al. Jul 1997 A
5645519 Lee et al. Jul 1997 A
5645565 Rudd et al. Jul 1997 A
5649372 Souza Jul 1997 A
5653677 Okada et al. Aug 1997 A
5653690 Booth et al. Aug 1997 A
5653722 Kieturakis Aug 1997 A
5657755 Desai Aug 1997 A
5662621 Lafontaine Sep 1997 A
5662663 Shallman Sep 1997 A
5667527 Cook Sep 1997 A
5669875 van Eerdenburg Sep 1997 A
5681276 Lundquist Oct 1997 A
5681279 Roper et al. Oct 1997 A
5681324 Kammerer et al. Oct 1997 A
5681330 Hughett et al. Oct 1997 A
5685820 Riek et al. Nov 1997 A
5690606 Slotman Nov 1997 A
5690656 Cope et al. Nov 1997 A
5690660 Kauker et al. Nov 1997 A
5695448 Kimura et al. Dec 1997 A
5695505 Yoon Dec 1997 A
5695511 Cano et al. Dec 1997 A
5700275 Bell et al. Dec 1997 A
5702438 Avitall Dec 1997 A
5704892 Adair Jan 1998 A
5709708 Thal Jan 1998 A
5711921 Langford Jan 1998 A
5716326 Dannan Feb 1998 A
5716375 Fowler Feb 1998 A
5725542 Yoon Mar 1998 A
5728094 Edwards Mar 1998 A
5730740 Wales et al. Mar 1998 A
5735849 Baden et al. Apr 1998 A
5741234 Aboul-Hosn Apr 1998 A
5741278 Stevens Apr 1998 A
5741285 McBrayer et al. Apr 1998 A
5741429 Donadio, III et al. Apr 1998 A
5743456 Jones et al. Apr 1998 A
5746759 Meade et al. May 1998 A
5749826 Faulkner May 1998 A
5749881 Sackier et al. May 1998 A
5749889 Bacich et al. May 1998 A
5752951 Yanik May 1998 A
5755731 Grinberg May 1998 A
5759150 Konou et al. Jun 1998 A
5759151 Sturges Jun 1998 A
5762604 Kieturakis Jun 1998 A
5766167 Eggers et al. Jun 1998 A
5766170 Eggers Jun 1998 A
5766205 Zvenyatsky et al. Jun 1998 A
5769849 Eggers Jun 1998 A
5776188 Shepherd et al. Jul 1998 A
5779701 McBrayer et al. Jul 1998 A
5779716 Cano et al. Jul 1998 A
5779720 Walder-Utz et al. Jul 1998 A
5779727 Orejola Jul 1998 A
5782859 Nicholas et al. Jul 1998 A
5782861 Cragg et al. Jul 1998 A
5782866 Wenstrom, Jr. Jul 1998 A
5791022 Bohman Aug 1998 A
5792113 Kramer et al. Aug 1998 A
5792153 Swain et al. Aug 1998 A
5792165 Klieman et al. Aug 1998 A
5797835 Green Aug 1998 A
5797928 Kogasaka Aug 1998 A
5797939 Yoon Aug 1998 A
5797941 Schulze et al. Aug 1998 A
5797959 Castro et al. Aug 1998 A
5797960 Stevens et al. Aug 1998 A
5800449 Wales Sep 1998 A
5800451 Buess et al. Sep 1998 A
5803903 Athas et al. Sep 1998 A
5807395 Mulier et al. Sep 1998 A
5808665 Green Sep 1998 A
5810805 Sutcu et al. Sep 1998 A
5810806 Ritchart et al. Sep 1998 A
5810849 Kontos Sep 1998 A
5810865 Koscher et al. Sep 1998 A
5810876 Kelleher Sep 1998 A
5810877 Roth et al. Sep 1998 A
5813976 Filipi et al. Sep 1998 A
5814026 Yoon Sep 1998 A
5814058 Carlson et al. Sep 1998 A
5817061 Goodwin et al. Oct 1998 A
5817107 Schaller Oct 1998 A
5817119 Klieman et al. Oct 1998 A
5818527 Yamaguchi et al. Oct 1998 A
5819736 Avny et al. Oct 1998 A
5823947 Yoon et al. Oct 1998 A
5824071 Nelson et al. Oct 1998 A
5827190 Palcic et al. Oct 1998 A
5827276 LeVeen et al. Oct 1998 A
5827281 Levin Oct 1998 A
5827299 Thomason et al. Oct 1998 A
5827323 Klieman et al. Oct 1998 A
5830221 Stein et al. Nov 1998 A
5830231 Geiges, Jr. Nov 1998 A
5833603 Kovacs et al. Nov 1998 A
5833700 Fogelberg et al. Nov 1998 A
5833703 Manushakian Nov 1998 A
5833715 Vachon et al. Nov 1998 A
5836960 Kolesa et al. Nov 1998 A
5843017 Yoon Dec 1998 A
5843097 Mayenberger et al. Dec 1998 A
5843121 Yoon Dec 1998 A
5849022 Sakashita et al. Dec 1998 A
5853374 Hart et al. Dec 1998 A
5855569 Komi Jan 1999 A
5855585 Kontos Jan 1999 A
5860913 Yamaya et al. Jan 1999 A
5860995 Berkelaar Jan 1999 A
5868762 Cragg et al. Feb 1999 A
5873849 Bernard Feb 1999 A
5876411 Kontos Mar 1999 A
5882331 Sasaki Mar 1999 A
5882344 Stouder, Jr. Mar 1999 A
5893846 Bales et al. Apr 1999 A
5893874 Bourque et al. Apr 1999 A
5893875 O'Connor et al. Apr 1999 A
5897487 Ouchi Apr 1999 A
5899919 Eubanks, Jr. et al. May 1999 A
5902238 Golden et al. May 1999 A
5902254 Magram May 1999 A
5904702 Ek et al. May 1999 A
5906625 Bito et al. May 1999 A
5908420 Parins et al. Jun 1999 A
5908429 Yoon Jun 1999 A
5911737 Lee et al. Jun 1999 A
5916146 Allotta et al. Jun 1999 A
5916147 Boury Jun 1999 A
5919207 Taheri Jul 1999 A
5921892 Easton Jul 1999 A
5921993 Yoon Jul 1999 A
5921997 Fogelberg et al. Jul 1999 A
5922008 Gimpelson Jul 1999 A
5925052 Simmons Jul 1999 A
5928255 Meade et al. Jul 1999 A
5928266 Kontos Jul 1999 A
5936536 Morris Aug 1999 A
5938661 Hahnen Aug 1999 A
5941815 Chang Aug 1999 A
5944718 Austin et al. Aug 1999 A
5951547 Gough et al. Sep 1999 A
5951549 Richardson et al. Sep 1999 A
5954720 Wilson et al. Sep 1999 A
5954731 Yoon Sep 1999 A
5957936 Yoon et al. Sep 1999 A
5957943 Vaitekunas Sep 1999 A
5957953 DiPoto et al. Sep 1999 A
5964782 Lafontaine et al. Oct 1999 A
5970581 Chadwick et al. Oct 1999 A
5971995 Rousseau Oct 1999 A
5972002 Bark et al. Oct 1999 A
5976074 Moriyama Nov 1999 A
5976075 Beane et al. Nov 1999 A
5976130 McBrayer et al. Nov 1999 A
5976131 Guglielmi et al. Nov 1999 A
5980539 Kontos Nov 1999 A
5980556 Giordano et al. Nov 1999 A
5984933 Yoon Nov 1999 A
5984938 Yoon Nov 1999 A
5984939 Yoon Nov 1999 A
5984950 Cragg et al. Nov 1999 A
5989182 Hori et al. Nov 1999 A
5993447 Blewett et al. Nov 1999 A
5993474 Ouchi Nov 1999 A
5995875 Blewett et al. Nov 1999 A
5997555 Kontos Dec 1999 A
6001120 Levin Dec 1999 A
6004269 Crowley et al. Dec 1999 A
6004330 Middleman et al. Dec 1999 A
6007566 Wenstrom, Jr. Dec 1999 A
6010515 Swain et al. Jan 2000 A
6012494 Balazs Jan 2000 A
6016452 Kasevich Jan 2000 A
6017356 Frederick et al. Jan 2000 A
6019770 Christoudias Feb 2000 A
6024708 Bales et al. Feb 2000 A
6024747 Kontos Feb 2000 A
6027522 Palmer Feb 2000 A
6030365 Laufer Feb 2000 A
6030384 Nezhat Feb 2000 A
6030634 Wu et al. Feb 2000 A
6033399 Gines Mar 2000 A
6033401 Edwards et al. Mar 2000 A
6036640 Corace et al. Mar 2000 A
6036685 Mueller Mar 2000 A
6050992 Nichols Apr 2000 A
6053927 Hamas Apr 2000 A
6053937 Edwards et al. Apr 2000 A
6059719 Yamamoto et al. May 2000 A
6066160 Colvin et al. May 2000 A
6068603 Suzuki May 2000 A
6068629 Haissaguerre et al. May 2000 A
6071233 Ishikawa et al. Jun 2000 A
6074408 Freeman Jun 2000 A
6086530 Mack Jul 2000 A
6086600 Kortenbach Jul 2000 A
6090105 Zepeda et al. Jul 2000 A
6090108 McBrayer et al. Jul 2000 A
6090129 Ouchi Jul 2000 A
6096046 Weiss Aug 2000 A
6102909 Chen et al. Aug 2000 A
6102926 Tartaglia et al. Aug 2000 A
6106473 Violante et al. Aug 2000 A
6106521 Blewett et al. Aug 2000 A
6109852 Shahinpoor et al. Aug 2000 A
6110154 Shimomura et al. Aug 2000 A
6110183 Cope Aug 2000 A
6113593 Tu et al. Sep 2000 A
6117144 Nobles et al. Sep 2000 A
6117158 Measamer et al. Sep 2000 A
6123718 Tu et al. Sep 2000 A
6131790 Piraka Oct 2000 A
6139555 Hart et al. Oct 2000 A
6141037 Upton et al. Oct 2000 A
6146391 Cigaina Nov 2000 A
6148222 Ramsey, III Nov 2000 A
6149653 Deslauriers Nov 2000 A
6149662 Pugliesi et al. Nov 2000 A
6152871 Foley et al. Nov 2000 A
6152920 Thompson et al. Nov 2000 A
6156006 Brosens et al. Dec 2000 A
6159200 Verdura et al. Dec 2000 A
6165175 Wampler et al. Dec 2000 A
6165184 Verdura et al. Dec 2000 A
6168570 Ferrera Jan 2001 B1
6168605 Measamer et al. Jan 2001 B1
6169269 Maynard Jan 2001 B1
6170130 Hamilton et al. Jan 2001 B1
6173872 Cohen Jan 2001 B1
6179776 Adams et al. Jan 2001 B1
6179832 Jones et al. Jan 2001 B1
6179837 Hooven Jan 2001 B1
6183420 Douk et al. Feb 2001 B1
6190353 Makower et al. Feb 2001 B1
6190383 Schmaltz et al. Feb 2001 B1
6190384 Ouchi Feb 2001 B1
6190399 Palmer et al. Feb 2001 B1
6203533 Ouchi Mar 2001 B1
6206872 Lafond et al. Mar 2001 B1
6206877 Kese et al. Mar 2001 B1
6206904 Ouchi Mar 2001 B1
6210409 Ellman et al. Apr 2001 B1
6214007 Anderson Apr 2001 B1
6214028 Yoon et al. Apr 2001 B1
6216043 Swanson et al. Apr 2001 B1
6228096 Marchand May 2001 B1
6231506 Hu et al. May 2001 B1
6234958 Snoke et al. May 2001 B1
6240312 Alfano et al. May 2001 B1
6245079 Nobles et al. Jun 2001 B1
6246914 de la Rama et al. Jun 2001 B1
6248124 Pedros et al. Jun 2001 B1
6258064 Smith et al. Jul 2001 B1
6261242 Roberts et al. Jul 2001 B1
6264664 Avellanet Jul 2001 B1
6270497 Sekino et al. Aug 2001 B1
6270505 Yoshida et al. Aug 2001 B1
6277136 Bonutti Aug 2001 B1
6283963 Regula Sep 2001 B1
6287304 Eggers Sep 2001 B1
6293909 Chu et al. Sep 2001 B1
6293952 Brosens et al. Sep 2001 B1
6296630 Altman et al. Oct 2001 B1
6314963 Vaska et al. Nov 2001 B1
6322578 Houle et al. Nov 2001 B1
6325534 Hawley et al. Dec 2001 B1
6326177 Schoenbach et al. Dec 2001 B1
6328730 Harkrider, Jr. Dec 2001 B1
6350267 Stefanchik Feb 2002 B1
6350269 Shipp et al. Feb 2002 B1
6350278 Lenker et al. Feb 2002 B1
6352503 Matsui et al. Mar 2002 B1
6352541 Kienzle et al. Mar 2002 B1
6352543 Cole Mar 2002 B1
6355013 van Muiden Mar 2002 B1
6355035 Manushakian Mar 2002 B1
6361534 Chen et al. Mar 2002 B1
6364879 Chen et al. Apr 2002 B1
6368340 Malecki et al. Apr 2002 B2
6371956 Wilson et al. Apr 2002 B1
6379366 Fleischman et al. Apr 2002 B1
6383195 Richard May 2002 B1
6383197 Conlon et al. May 2002 B1
6387671 Rubinsky et al. May 2002 B1
6391029 Hooven et al. May 2002 B1
6398708 Hastings et al. Jun 2002 B1
6402735 Langevin Jun 2002 B1
6402746 Whayne et al. Jun 2002 B1
6406440 Stefanchik Jun 2002 B1
6409727 Bales et al. Jun 2002 B1
6409733 Conlon et al. Jun 2002 B1
6419639 Walther et al. Jul 2002 B2
6419641 Mark et al. Jul 2002 B1
6427089 Knowlton Jul 2002 B1
6431500 Jacobs et al. Aug 2002 B1
6436107 Wang et al. Aug 2002 B1
6443970 Schulze et al. Sep 2002 B1
6443988 Felt et al. Sep 2002 B2
6447444 Avni et al. Sep 2002 B1
6447511 Slater Sep 2002 B1
6447523 Middleman et al. Sep 2002 B1
6454783 Piskun Sep 2002 B1
6454785 De Hoyos Garza Sep 2002 B2
6458074 Matsui et al. Oct 2002 B1
6458076 Pruitt Oct 2002 B1
6464701 Hooven et al. Oct 2002 B1
6464702 Schulze et al. Oct 2002 B2
6470218 Behl Oct 2002 B1
6475104 Lutz et al. Nov 2002 B1
6485411 Konstorum et al. Nov 2002 B1
6489745 Koreis Dec 2002 B1
6491626 Stone et al. Dec 2002 B1
6491627 Komi Dec 2002 B1
6491691 Morley et al. Dec 2002 B1
6493590 Wessman et al. Dec 2002 B1
6494893 Dubrul et al. Dec 2002 B2
6500176 Truckai et al. Dec 2002 B1
6503192 Ouchi Jan 2003 B1
6506190 Walshe Jan 2003 B1
6508827 Manhes Jan 2003 B1
6514239 Shimmura et al. Feb 2003 B2
6517534 McGovern et al. Feb 2003 B1
6520954 Ouchi Feb 2003 B2
6526320 Mitchell Feb 2003 B2
6527753 Sekine et al. Mar 2003 B2
6527782 Hogg et al. Mar 2003 B2
6530880 Pagliuca Mar 2003 B2
6530922 Cosman et al. Mar 2003 B2
6535764 Imran et al. Mar 2003 B2
6537200 Leysieffer et al. Mar 2003 B2
6543456 Freeman Apr 2003 B1
6551270 Bimbo et al. Apr 2003 B1
6551356 Rousseau Apr 2003 B2
6554766 Maeda et al. Apr 2003 B2
6554823 Palmer et al. Apr 2003 B2
6554829 Schulze et al. Apr 2003 B2
6558384 Mayenberger May 2003 B2
6562034 Edwards et al. May 2003 B2
6562035 Levin May 2003 B1
6562052 Nobles et al. May 2003 B2
6569085 Kortenbach et al. May 2003 B2
6569091 Diokno et al. May 2003 B2
6569120 Green et al. May 2003 B1
6569159 Edwards et al. May 2003 B1
6572629 Kalloo et al. Jun 2003 B2
6572635 Bonutti Jun 2003 B1
6575988 Rousseau Jun 2003 B2
6579311 Makower Jun 2003 B1
6581889 Carpenter et al. Jun 2003 B2
6585642 Christopher Jul 2003 B2
6585717 Wittenberger et al. Jul 2003 B1
6587750 Gerbi et al. Jul 2003 B2
6592559 Pakter et al. Jul 2003 B1
6592603 Lasner Jul 2003 B2
6594971 Addy et al. Jul 2003 B1
6602262 Griego et al. Aug 2003 B2
6605105 Cuschieri et al. Aug 2003 B1
6610072 Christy et al. Aug 2003 B1
6610074 Santilli Aug 2003 B2
6613038 Bonutti et al. Sep 2003 B2
6613068 Ouchi Sep 2003 B2
6616632 Sharp et al. Sep 2003 B2
6620193 Lau et al. Sep 2003 B1
6623448 Slater Sep 2003 B2
6626919 Swanstrom Sep 2003 B1
6632171 Iddan et al. Oct 2003 B2
6632229 Yamanouchi Oct 2003 B1
6632234 Kieturakis et al. Oct 2003 B2
6638275 McGaffigan et al. Oct 2003 B1
6638286 Burbank et al. Oct 2003 B1
6645225 Atkinson Nov 2003 B1
6652518 Wellman et al. Nov 2003 B2
6652521 Schulze Nov 2003 B2
6652545 Shipp et al. Nov 2003 B2
6652551 Heiss Nov 2003 B1
6656194 Gannoe et al. Dec 2003 B1
6663641 Kovac et al. Dec 2003 B1
6663655 Ginn et al. Dec 2003 B2
6666854 Lange Dec 2003 B1
6672338 Esashi et al. Jan 2004 B1
6673058 Snow Jan 2004 B2
6673070 Edwards et al. Jan 2004 B2
6673087 Chang et al. Jan 2004 B1
6673092 Bacher Jan 2004 B1
6676685 Pedros et al. Jan 2004 B2
6679882 Kornerup Jan 2004 B1
6684938 Tsujita et al. Feb 2004 B2
6685628 Vu Feb 2004 B2
6685724 Haluck Feb 2004 B1
6692445 Roberts et al. Feb 2004 B2
6692462 Mackenzie et al. Feb 2004 B2
6692493 McGovern et al. Feb 2004 B2
6695867 Ginn et al. Feb 2004 B2
6699180 Kobayashi Mar 2004 B2
6699256 Logan et al. Mar 2004 B1
6699263 Cope Mar 2004 B2
6706018 Westlund et al. Mar 2004 B2
6708066 Herbst et al. Mar 2004 B2
6709188 Ushimaru Mar 2004 B2
6709445 Boebel et al. Mar 2004 B2
6716226 Sixto, Jr. et al. Apr 2004 B2
6731875 Kartalopoulos May 2004 B1
6736822 McClellan et al. May 2004 B2
6740030 Martone et al. May 2004 B2
6740082 Shadduck May 2004 B2
6743166 Berci et al. Jun 2004 B2
6743226 Cosman et al. Jun 2004 B2
6743239 Kuehn et al. Jun 2004 B1
6743240 Smith et al. Jun 2004 B2
6749560 Konstorum et al. Jun 2004 B1
6749609 Lunsford et al. Jun 2004 B1
6752768 Burdorff et al. Jun 2004 B2
6752811 Chu et al. Jun 2004 B2
6752822 Jespersen Jun 2004 B2
6758857 Cioanta et al. Jul 2004 B2
6761685 Adams et al. Jul 2004 B2
6761718 Madsen Jul 2004 B2
6761722 Cole et al. Jul 2004 B2
6767356 Kanner et al. Jul 2004 B2
6773434 Ciarrocca Aug 2004 B2
6776165 Jin Aug 2004 B2
6776787 Phung et al. Aug 2004 B2
6780151 Grabover et al. Aug 2004 B2
6780352 Jacobson Aug 2004 B2
6783491 Saadat et al. Aug 2004 B2
6786382 Hoffman Sep 2004 B1
6786864 Matsuura et al. Sep 2004 B2
6786905 Swanson et al. Sep 2004 B2
6788977 Fenn et al. Sep 2004 B2
6790173 Saadat et al. Sep 2004 B2
6790217 Schulze et al. Sep 2004 B2
6795728 Chornenky et al. Sep 2004 B2
6800056 Tartaglia et al. Oct 2004 B2
6808491 Kortenbach et al. Oct 2004 B2
6814697 Ouchi Nov 2004 B2
6817974 Cooper et al. Nov 2004 B2
6818007 Dampney et al. Nov 2004 B1
6821285 Laufer et al. Nov 2004 B2
6824548 Smith et al. Nov 2004 B2
6830545 Bendall Dec 2004 B2
6835200 Laufer et al. Dec 2004 B2
6836688 Ingle et al. Dec 2004 B2
6837847 Ewers et al. Jan 2005 B2
6840246 Downing Jan 2005 B2
6840938 Morley et al. Jan 2005 B1
6843794 Sixto, Jr. et al. Jan 2005 B2
6852078 Ouchi Feb 2005 B2
6861250 Cole et al. Mar 2005 B1
6866627 Nozue Mar 2005 B2
6866628 Goodman et al. Mar 2005 B2
6869394 Ishibiki Mar 2005 B2
6869395 Page et al. Mar 2005 B2
6869398 Obenchain et al. Mar 2005 B2
6878106 Herrmann Apr 2005 B1
6878110 Yang et al. Apr 2005 B2
6881213 Ryan et al. Apr 2005 B2
6881216 Di Caprio et al. Apr 2005 B2
6884213 Raz et al. Apr 2005 B2
6887255 Shimm May 2005 B2
6889089 Behl et al. May 2005 B2
6890295 Michels et al. May 2005 B2
6896683 Gadberry et al. May 2005 B1
6896692 Ginn et al. May 2005 B2
6899710 Hooven May 2005 B2
6908427 Fleener et al. Jun 2005 B2
6908476 Jud et al. Jun 2005 B2
6911019 Mulier et al. Jun 2005 B2
6913613 Schwarz et al. Jul 2005 B2
6916284 Moriyama Jul 2005 B2
6918871 Schulze Jul 2005 B2
6918906 Long Jul 2005 B2
6918908 Bonner et al. Jul 2005 B2
6926723 Mulhauser et al. Aug 2005 B1
6926725 Cooke et al. Aug 2005 B2
6932810 Ryan Aug 2005 B2
6932824 Roop et al. Aug 2005 B1
6932827 Cole Aug 2005 B2
6932834 Lizardi et al. Aug 2005 B2
6936003 Iddan Aug 2005 B2
6939290 Iddan Sep 2005 B2
6939292 Mizuno Sep 2005 B2
6939327 Hall et al. Sep 2005 B2
6939347 Thompson Sep 2005 B2
6942613 Ewers et al. Sep 2005 B2
6944490 Chow Sep 2005 B1
6945472 Wuttke et al. Sep 2005 B2
6945979 Kortenbach et al. Sep 2005 B2
6949096 Davison et al. Sep 2005 B2
6955641 Lubock Oct 2005 B2
6955683 Bonutti Oct 2005 B2
6958035 Friedman et al. Oct 2005 B2
6960162 Saadat et al. Nov 2005 B2
6960163 Ewers et al. Nov 2005 B2
6960183 Nicolette Nov 2005 B2
6962587 Johnson et al. Nov 2005 B2
6964662 Kidooka Nov 2005 B2
6966909 Marshall et al. Nov 2005 B2
6966919 Sixto, Jr. et al. Nov 2005 B2
6967462 Landis Nov 2005 B1
6971988 Orban, III Dec 2005 B2
6972017 Smith et al. Dec 2005 B2
6974411 Belson Dec 2005 B2
6976992 Sachatello et al. Dec 2005 B2
6980858 Fuimaono et al. Dec 2005 B2
6984203 Tartaglia et al. Jan 2006 B2
6984205 Gazdzinski Jan 2006 B2
6986738 Glukhovsky et al. Jan 2006 B2
6986774 Middleman et al. Jan 2006 B2
6988987 Ishikawa et al. Jan 2006 B2
6989028 Lashinski et al. Jan 2006 B2
6991602 Nakazawa et al. Jan 2006 B2
6991627 Madhani et al. Jan 2006 B2
6991631 Woloszko et al. Jan 2006 B2
6994706 Chornenky et al. Feb 2006 B2
6994708 Manzo Feb 2006 B2
6997870 Couvillon, Jr. Feb 2006 B2
6997931 Sauer et al. Feb 2006 B2
7000818 Shelton, IV et al. Feb 2006 B2
7001329 Kobayashi et al. Feb 2006 B2
7001341 Gellman et al. Feb 2006 B2
7008375 Weisel Mar 2006 B2
7008419 Shadduck Mar 2006 B2
7009634 Iddan et al. Mar 2006 B2
7010340 Scarantino et al. Mar 2006 B2
7011669 Kimblad Mar 2006 B2
7018373 Suzuki Mar 2006 B2
7020531 Colliou et al. Mar 2006 B1
7025580 Heagy et al. Apr 2006 B2
7025721 Cohen et al. Apr 2006 B2
7029435 Nakao Apr 2006 B2
7029438 Morin et al. Apr 2006 B2
7029450 Gellman Apr 2006 B2
7032600 Fukuda et al. Apr 2006 B2
7035680 Partridge et al. Apr 2006 B2
7037290 Gardeski et al. May 2006 B2
7041052 Saadat et al. May 2006 B2
7052454 Taylor May 2006 B2
7052489 Griego et al. May 2006 B2
7056330 Gayton Jun 2006 B2
7060024 Long et al. Jun 2006 B2
7060025 Long et al. Jun 2006 B2
7063697 Slater Jun 2006 B2
7063715 Onuki et al. Jun 2006 B2
7066879 Fowler et al. Jun 2006 B2
7066936 Ryan Jun 2006 B2
7070559 Adams et al. Jul 2006 B2
7070602 Smith et al. Jul 2006 B2
7076305 Imran et al. Jul 2006 B2
7083618 Couture et al. Aug 2006 B2
7083620 Jahns et al. Aug 2006 B2
7083629 Weller et al. Aug 2006 B2
7083635 Ginn Aug 2006 B2
7087010 Ootawara et al. Aug 2006 B2
7087071 Nicholas et al. Aug 2006 B2
7088923 Haruyama Aug 2006 B2
7090673 Dycus et al. Aug 2006 B2
7090683 Brock et al. Aug 2006 B2
7090685 Kortenbach et al. Aug 2006 B2
7093518 Gmeilbauer Aug 2006 B2
7101371 Dycus et al. Sep 2006 B2
7101372 Dycus et al. Sep 2006 B2
7101373 Dycus et al. Sep 2006 B2
7105000 McBrayer Sep 2006 B2
7105005 Blake Sep 2006 B2
7108696 Daniel et al. Sep 2006 B2
7108703 Danitz et al. Sep 2006 B2
7112208 Morris et al. Sep 2006 B2
7115092 Park et al. Oct 2006 B2
7115124 Xiao Oct 2006 B1
7115785 Guggenheim et al. Oct 2006 B2
7117703 Kato et al. Oct 2006 B2
7118531 Krill Oct 2006 B2
7118578 West, Jr. et al. Oct 2006 B2
7118587 Dycus et al. Oct 2006 B2
7122605 Ohrbom et al. Oct 2006 B2
7128708 Saadat et al. Oct 2006 B2
7130697 Chornenky et al. Oct 2006 B2
RE39415 Bales et al. Nov 2006 E
7131978 Sancoff et al. Nov 2006 B2
7131979 DiCarlo et al. Nov 2006 B2
7131980 Field et al. Nov 2006 B1
7137980 Buysse et al. Nov 2006 B2
7137981 Long Nov 2006 B2
7146984 Stack et al. Dec 2006 B2
7147650 Lee Dec 2006 B2
7150097 Sremcich et al. Dec 2006 B2
7150655 Mastrototaro et al. Dec 2006 B2
7150750 Damarati Dec 2006 B2
7152488 Hedrich et al. Dec 2006 B2
7153321 Andrews Dec 2006 B2
7156845 Mulier et al. Jan 2007 B2
7160296 Pearson et al. Jan 2007 B2
7163525 Franer Jan 2007 B2
7169104 Ueda et al. Jan 2007 B2
7169115 Nobis et al. Jan 2007 B2
7172714 Jacobson Feb 2007 B2
7175591 Kaladelfos Feb 2007 B2
7179254 Pendekanti et al. Feb 2007 B2
7186265 Sharkawy et al. Mar 2007 B2
7188627 Nelson et al. Mar 2007 B2
7189231 Clague et al. Mar 2007 B2
7195612 van Sloten et al. Mar 2007 B2
7195631 Dumbauld Mar 2007 B2
7204804 Zirps et al. Apr 2007 B2
7204820 Akahoshi Apr 2007 B2
7204840 Skakoon et al. Apr 2007 B2
7207997 Shipp et al. Apr 2007 B2
7208005 Frecker et al. Apr 2007 B2
7211089 Kear et al. May 2007 B2
7211092 Hughett May 2007 B2
7220227 Sasaki et al. May 2007 B2
7223271 Muramatsu et al. May 2007 B2
7223272 Francese et al. May 2007 B2
7226458 Kaplan et al. Jun 2007 B2
7229438 Young Jun 2007 B2
7232414 Gonzalez Jun 2007 B2
7232445 Kortenbach et al. Jun 2007 B2
7235084 Skakoon et al. Jun 2007 B2
7235089 McGuckin, Jr. Jun 2007 B1
7241290 Doyle et al. Jul 2007 B2
7241295 Maguire Jul 2007 B2
7244228 Lubowski Jul 2007 B2
7250027 Barry Jul 2007 B2
7252660 Kunz Aug 2007 B2
7255675 Gertner et al. Aug 2007 B2
7261725 Binmoeller Aug 2007 B2
7261728 Long et al. Aug 2007 B2
7270663 Nakao Sep 2007 B2
7288075 Parihar et al. Oct 2007 B2
7290615 Christanti et al. Nov 2007 B2
7291127 Eidenschink Nov 2007 B2
7294139 Gengler Nov 2007 B1
7301250 Cassel Nov 2007 B2
7306597 Manzo Dec 2007 B2
7308828 Hashimoto Dec 2007 B2
7311107 Harel et al. Dec 2007 B2
7318802 Suzuki et al. Jan 2008 B2
7320695 Carroll Jan 2008 B2
7322934 Miyake et al. Jan 2008 B2
7323006 Andreas et al. Jan 2008 B2
7329256 Johnson et al. Feb 2008 B2
7329257 Kanehira et al. Feb 2008 B2
7329383 Stinson Feb 2008 B2
7331968 Arp et al. Feb 2008 B2
7335220 Khosravi et al. Feb 2008 B2
7341554 Sekine et al. Mar 2008 B2
7344536 Lunsford et al. Mar 2008 B1
7349223 Haemer et al. Mar 2008 B2
7352387 Yamamoto Apr 2008 B2
7357806 Rivera et al. Apr 2008 B2
7364582 Lee Apr 2008 B2
7367939 Smith et al. May 2008 B2
7371215 Colliou et al. May 2008 B2
7381216 Buzzard et al. Jun 2008 B2
7390324 Whalen et al. Jun 2008 B2
7393322 Wenchell Jul 2008 B2
7402162 Ouchi Jul 2008 B2
7404791 Linares et al. Jul 2008 B2
7410483 Danitz et al. Aug 2008 B2
7413563 Corcoran et al. Aug 2008 B2
7416554 Lam et al. Aug 2008 B2
7422590 Kupferschmid et al. Sep 2008 B2
7431694 Stefanchik et al. Oct 2008 B2
7435229 Wolf Oct 2008 B2
7435257 Lashinski et al. Oct 2008 B2
7441507 Teraura et al. Oct 2008 B2
7442166 Huang et al. Oct 2008 B2
7452327 Durgin et al. Nov 2008 B2
7455208 Wales et al. Nov 2008 B2
7455675 Schur et al. Nov 2008 B2
7468066 Vargas et al. Dec 2008 B2
7476237 Taniguchi et al. Jan 2009 B2
7479104 Lau et al. Jan 2009 B2
7485093 Glukhovsky Feb 2009 B2
7488295 Burbank et al. Feb 2009 B2
7494499 Nagase et al. Feb 2009 B2
7497867 Lasner et al. Mar 2009 B2
7498950 Ertas et al. Mar 2009 B1
7507200 Okada Mar 2009 B2
7507239 Shadduck Mar 2009 B2
7510107 Timm et al. Mar 2009 B2
7511733 Takizawa et al. Mar 2009 B2
7514568 Freeman Apr 2009 B2
7515953 Madar et al. Apr 2009 B2
7520876 Ressemann et al. Apr 2009 B2
7520950 Saadat et al. Apr 2009 B2
7524281 Chu et al. Apr 2009 B2
7524302 Tower Apr 2009 B2
7534228 Williams May 2009 B2
7535570 Muraishi May 2009 B2
7536217 Minai et al. May 2009 B2
7540872 Schechter et al. Jun 2009 B2
7542807 Bertolero et al. Jun 2009 B2
7544195 Lunsford et al. Jun 2009 B2
7544203 Chin et al. Jun 2009 B2
7547310 Whitfield Jun 2009 B2
7548040 Lee et al. Jun 2009 B2
7549564 Boudreaux Jun 2009 B2
7549990 Canady Jun 2009 B2
7549991 Lu et al. Jun 2009 B2
7549998 Braun Jun 2009 B2
7553278 Kucklick Jun 2009 B2
7553298 Hunt et al. Jun 2009 B2
7559452 Wales et al. Jul 2009 B2
7559887 Dannan Jul 2009 B2
7559916 Smith et al. Jul 2009 B2
7560006 Rakos et al. Jul 2009 B2
7561907 Fuimaono et al. Jul 2009 B2
7561916 Hunt et al. Jul 2009 B2
7565201 Blackmore et al. Jul 2009 B2
7566300 Devierre et al. Jul 2009 B2
7566334 Christian et al. Jul 2009 B2
7575144 Ortiz et al. Aug 2009 B2
7575548 Takemoto et al. Aug 2009 B2
7578832 Johnson et al. Aug 2009 B2
7579005 Keeler et al. Aug 2009 B2
7579550 Dayton et al. Aug 2009 B2
7582096 Gellman et al. Sep 2009 B2
7588177 Racenet Sep 2009 B2
7588557 Nakao Sep 2009 B2
7591781 Hirata Sep 2009 B2
7591783 Boulais et al. Sep 2009 B2
7597229 Boudreaux et al. Oct 2009 B2
7604150 Boudreaux Oct 2009 B2
7608083 Lee et al. Oct 2009 B2
7611479 Cragg et al. Nov 2009 B2
7612084 James et al. Nov 2009 B2
7615002 Rothweiler et al. Nov 2009 B2
7615003 Stefanchik et al. Nov 2009 B2
7615005 Stefanchik et al. Nov 2009 B2
7615058 Sixto, Jr. et al. Nov 2009 B2
7615067 Lee et al. Nov 2009 B2
7618398 Holman et al. Nov 2009 B2
7618437 Nakao Nov 2009 B2
7621927 Messerly et al. Nov 2009 B2
7621936 Cragg et al. Nov 2009 B2
7628792 Guerra Dec 2009 B2
7628797 Tieu et al. Dec 2009 B2
7632250 Smith et al. Dec 2009 B2
7635373 Ortiz Dec 2009 B2
7637903 Lentz et al. Dec 2009 B2
7637905 Saadat et al. Dec 2009 B2
7645288 McKenna et al. Jan 2010 B2
7648457 Stefanchik et al. Jan 2010 B2
7648519 Lee et al. Jan 2010 B2
7650742 Ushijima Jan 2010 B2
7651483 Byrum et al. Jan 2010 B2
7651509 Bojarski et al. Jan 2010 B2
7653438 Deem et al. Jan 2010 B2
7654431 Hueil et al. Feb 2010 B2
7655004 Long Feb 2010 B2
7658738 Nobis et al. Feb 2010 B2
7662089 Okada et al. Feb 2010 B2
7666180 Holsten et al. Feb 2010 B2
7666203 Chanduszko et al. Feb 2010 B2
7670282 Mathis Mar 2010 B2
7670336 Young et al. Mar 2010 B2
7670346 Whitfield Mar 2010 B2
7674259 Shadduck Mar 2010 B2
7674275 Martin et al. Mar 2010 B2
7678043 Gilad Mar 2010 B2
7680543 Azure Mar 2010 B2
7684599 Horn et al. Mar 2010 B2
7684851 Miyake et al. Mar 2010 B2
7686826 Lee et al. Mar 2010 B2
7691103 Fernandez et al. Apr 2010 B2
7697970 Uchiyama et al. Apr 2010 B2
7699835 Lee et al. Apr 2010 B2
7699864 Kick et al. Apr 2010 B2
7708756 Nobis et al. May 2010 B2
7710563 Betzig et al. May 2010 B2
7713189 Hanke May 2010 B2
7713270 Suzuki May 2010 B2
7721742 Kalloo et al. May 2010 B2
7722631 Mikkaichi et al. May 2010 B2
7727242 Sepetka et al. Jun 2010 B2
7727246 Sixto, Jr. et al. Jun 2010 B2
7727248 Smith et al. Jun 2010 B2
7727249 Rahmani Jun 2010 B2
7731725 Gadberry et al. Jun 2010 B2
7736374 Vaughan et al. Jun 2010 B2
7744591 Rioux et al. Jun 2010 B2
7744613 Ewers et al. Jun 2010 B2
7744615 Couture Jun 2010 B2
7749161 Beckman et al. Jul 2010 B2
7749163 Mulac et al. Jul 2010 B2
7751866 Aoki et al. Jul 2010 B2
7751869 Rioux et al. Jul 2010 B2
7753901 Piskun et al. Jul 2010 B2
7753933 Ginn et al. Jul 2010 B2
7758577 Nobis et al. Jul 2010 B2
7758598 Conlon et al. Jul 2010 B2
7762949 Nakao Jul 2010 B2
7762959 Bilsbury Jul 2010 B2
7762960 Timberlake et al. Jul 2010 B2
7762998 Birk et al. Jul 2010 B2
7763012 Petrick et al. Jul 2010 B2
7765010 Chornenky et al. Jul 2010 B2
7766896 Kornkven Volk et al. Aug 2010 B2
7770584 Danek et al. Aug 2010 B2
7771416 Spivey et al. Aug 2010 B2
7771437 Hogg et al. Aug 2010 B2
7776035 Rick et al. Aug 2010 B2
7780639 Van Lue Aug 2010 B2
7780683 Roue et al. Aug 2010 B2
7780691 Stefanchik Aug 2010 B2
7784663 Shelton, IV Aug 2010 B2
7785348 Kuhns et al. Aug 2010 B2
7789825 Nobis et al. Sep 2010 B2
7794409 Damarati Sep 2010 B2
7794447 Dann et al. Sep 2010 B2
7794458 McIntyre et al. Sep 2010 B2
7794475 Hess et al. Sep 2010 B2
7798386 Schall et al. Sep 2010 B2
7798750 Clark Sep 2010 B2
7798960 Jaeger Sep 2010 B2
7813590 Horn et al. Oct 2010 B2
7813789 Glukhovsky Oct 2010 B2
7815565 Stefanchik et al. Oct 2010 B2
7815566 Stefanchik et al. Oct 2010 B2
7815651 Skakoon et al. Oct 2010 B2
7815659 Conlon et al. Oct 2010 B2
7815662 Spivey et al. Oct 2010 B2
7819836 Levine et al. Oct 2010 B2
7828186 Wales Nov 2010 B2
7828808 Hinman et al. Nov 2010 B2
7828809 Skakoon et al. Nov 2010 B2
7833156 Williams et al. Nov 2010 B2
7833231 Skakoon et al. Nov 2010 B2
7833238 Nakao Nov 2010 B2
7837615 Le et al. Nov 2010 B2
7842028 Lee Nov 2010 B2
7842050 Diduch et al. Nov 2010 B2
7842068 Ginn Nov 2010 B2
7846087 Stefanchik et al. Dec 2010 B2
7846107 Hoffman et al. Dec 2010 B2
7846171 Kullas et al. Dec 2010 B2
7850660 Uth et al. Dec 2010 B2
7850686 Nobis et al. Dec 2010 B2
7850712 Conlon et al. Dec 2010 B2
7857183 Shelton, IV Dec 2010 B2
7857820 Skakoon et al. Dec 2010 B2
7862546 Conlon et al. Jan 2011 B2
7862553 Ewaschuk Jan 2011 B2
7862572 Meade et al. Jan 2011 B2
7862582 Ortiz et al. Jan 2011 B2
7867216 Wahr et al. Jan 2011 B2
7871371 Komiya et al. Jan 2011 B2
7875042 Martin et al. Jan 2011 B2
7879004 Seibel et al. Feb 2011 B2
7883458 Hamel Feb 2011 B2
7887530 Zemlok et al. Feb 2011 B2
7887558 Lin et al. Feb 2011 B2
7892200 Birk et al. Feb 2011 B2
7892220 Faller et al. Feb 2011 B2
7896804 Uchimura et al. Mar 2011 B2
7896887 Rimbaugh et al. Mar 2011 B2
7905828 Brock et al. Mar 2011 B2
7905830 Stefanchik et al. Mar 2011 B2
7909809 Scopton et al. Mar 2011 B2
7914513 Voorhees, Jr. Mar 2011 B2
7916809 Tsushima Mar 2011 B2
7918783 Maseda et al. Apr 2011 B2
7918785 Okada et al. Apr 2011 B2
7918844 Byrum et al. Apr 2011 B2
7918845 Saadat et al. Apr 2011 B2
7918848 Lau et al. Apr 2011 B2
7918869 Saadat et al. Apr 2011 B2
7922650 McWeeney et al. Apr 2011 B2
7922717 Sugita Apr 2011 B2
7922739 Downey Apr 2011 B2
7922743 Heinrich et al. Apr 2011 B2
7927271 Dimitriou et al. Apr 2011 B2
7931624 Smith et al. Apr 2011 B2
7931661 Saadat et al. Apr 2011 B2
7935130 Williams May 2011 B2
7937143 Demarais et al. May 2011 B2
7945332 Schechter May 2011 B2
7947000 Vargas et al. May 2011 B2
7951073 Freed May 2011 B2
7953326 Farr et al. May 2011 B2
7955298 Carroll et al. Jun 2011 B2
7955340 Michlitsch et al. Jun 2011 B2
7955355 Chin Jun 2011 B2
7959627 Utley et al. Jun 2011 B2
7959629 Young et al. Jun 2011 B2
7959642 Nobis et al. Jun 2011 B2
7963192 Mayenberger et al. Jun 2011 B2
7963912 Zwolinski et al. Jun 2011 B2
7963975 Criscuolo Jun 2011 B2
7965180 Koyama Jun 2011 B2
7967808 Fitzgerald et al. Jun 2011 B2
7967842 Bakos Jun 2011 B2
7969473 Kotoda Jun 2011 B2
7972330 Alejandro et al. Jul 2011 B2
7972333 Nishimura Jul 2011 B2
7976458 Stefanchik et al. Jul 2011 B2
7976552 Suzuki Jul 2011 B2
7985239 Suzuki Jul 2011 B2
7985830 Mance et al. Jul 2011 B2
7988618 Mikkaichi et al. Aug 2011 B2
7988685 Ziaie et al. Aug 2011 B2
7988690 Chanduszko et al. Aug 2011 B2
7998132 Gregorich et al. Aug 2011 B2
8007474 Uth et al. Aug 2011 B2
8007495 McDaniel et al. Aug 2011 B2
8021358 Doyle et al. Sep 2011 B2
8021362 Deem et al. Sep 2011 B2
8021378 Sixto, Jr. et al. Sep 2011 B2
8029504 Long Oct 2011 B2
8034046 Eidenschink Oct 2011 B2
8037591 Spivey et al. Oct 2011 B2
8038596 Miyake et al. Oct 2011 B2
8038612 Paz Oct 2011 B2
8043289 Behl et al. Oct 2011 B2
8048060 Griffin et al. Nov 2011 B2
8048067 Davalos et al. Nov 2011 B2
8048108 Sibbitt, Jr. et al. Nov 2011 B2
8052597 Boulais Nov 2011 B2
8052699 Sherwinter Nov 2011 B1
8057462 Weitzner et al. Nov 2011 B2
8057510 Ginn et al. Nov 2011 B2
8062306 Nobis et al. Nov 2011 B2
8062311 Litscher et al. Nov 2011 B2
8066632 Dario et al. Nov 2011 B2
8066702 Rittman, III et al. Nov 2011 B2
8070743 Kagan et al. Dec 2011 B2
8070759 Stefanchik et al. Dec 2011 B2
8070804 Hyde et al. Dec 2011 B2
8075478 Campos Dec 2011 B2
8075567 Taylor et al. Dec 2011 B2
8075572 Stefanchik Dec 2011 B2
8075573 Gambale et al. Dec 2011 B2
8075587 Ginn Dec 2011 B2
8083787 Korb et al. Dec 2011 B2
8088062 Zwolinski Jan 2012 B2
8092374 Smith et al. Jan 2012 B2
8092549 Hillis et al. Jan 2012 B2
8096459 Ortiz et al. Jan 2012 B2
8096941 Fowler et al. Jan 2012 B2
8096998 Cresina Jan 2012 B2
8097001 Nakao Jan 2012 B2
8100922 Griffith Jan 2012 B2
8105342 Onuki et al. Jan 2012 B2
8109872 Kennedy, II et al. Feb 2012 B2
8109919 Kraft et al. Feb 2012 B2
8109926 Azure Feb 2012 B2
8114072 Long et al. Feb 2012 B2
8114113 Becker Feb 2012 B2
8114119 Spivey et al. Feb 2012 B2
8115447 Toya et al. Feb 2012 B2
8118738 Larkin Feb 2012 B2
8118821 Mouw Feb 2012 B2
8118834 Goraltchouk et al. Feb 2012 B1
8118835 Weisel et al. Feb 2012 B2
8123677 Fujimori Feb 2012 B2
8131371 Demarals et al. Mar 2012 B2
8147424 Kassab et al. Apr 2012 B2
8157813 Ko et al. Apr 2012 B2
8157817 Bonadio et al. Apr 2012 B2
8157834 Conlon Apr 2012 B2
8159549 Glukhovsky et al. Apr 2012 B2
8167894 Miles et al. May 2012 B2
8172772 Zwolinski et al. May 2012 B2
8182414 Handa et al. May 2012 B2
8187166 Kuth et al. May 2012 B2
8200334 Min et al. Jun 2012 B1
8202265 Boulais Jun 2012 B2
8202295 Kaplan Jun 2012 B2
8206295 Kaul Jun 2012 B2
8211119 Palmer et al. Jul 2012 B2
8211125 Spivey Jul 2012 B2
8216224 Morris et al. Jul 2012 B2
8216252 Vaughan et al. Jul 2012 B2
8216255 Smith et al. Jul 2012 B2
8221310 Saadat et al. Jul 2012 B2
8221411 Francischelli et al. Jul 2012 B2
8222385 Yoshizaki et al. Jul 2012 B2
8241204 Spivey Aug 2012 B2
8241309 Miles et al. Aug 2012 B2
8246633 Omori Aug 2012 B2
8251068 Schnell Aug 2012 B2
8252057 Fox Aug 2012 B2
8262563 Bakos et al. Sep 2012 B2
8262655 Ghabrial et al. Sep 2012 B2
8262680 Swain et al. Sep 2012 B2
8267854 Asada et al. Sep 2012 B2
8277373 Maahs et al. Oct 2012 B2
8282665 Kieturakis et al. Oct 2012 B2
8298161 Vargas Oct 2012 B2
8303581 Arts et al. Nov 2012 B2
8308682 Kramer et al. Nov 2012 B2
8308738 Nobis et al. Nov 2012 B2
8308743 Matsuno et al. Nov 2012 B2
8313496 Sauer et al. Nov 2012 B2
8317806 Coe et al. Nov 2012 B2
8317814 Karasawa et al. Nov 2012 B2
8328836 Conlon et al. Dec 2012 B2
8333691 Schaaf Dec 2012 B2
8333777 Schaller et al. Dec 2012 B2
8337394 Vakharia Dec 2012 B2
8337492 Kunis et al. Dec 2012 B2
8337510 Rieber et al. Dec 2012 B2
8343041 Byers et al. Jan 2013 B2
8348827 Zwolinski Jan 2013 B2
8353487 Trusty et al. Jan 2013 B2
8357170 Stefanchik Jan 2013 B2
8359093 Wariar Jan 2013 B2
8361066 Long et al. Jan 2013 B2
8361112 Carroll, II et al. Jan 2013 B2
8366606 Watanabe et al. Feb 2013 B2
8366733 Gabel et al. Feb 2013 B2
8377044 Coe et al. Feb 2013 B2
8377057 Rick et al. Feb 2013 B2
8382790 Uenohara et al. Feb 2013 B2
8388653 Nobis et al. Mar 2013 B2
8394090 Ootsubo Mar 2013 B2
8403926 Nobis et al. Mar 2013 B2
8409076 Pang et al. Apr 2013 B2
8409197 Slater Apr 2013 B2
8409200 Holcomb et al. Apr 2013 B2
8425505 Long Apr 2013 B2
8430811 Hess et al. Apr 2013 B2
8449452 Iddan et al. May 2013 B2
8449538 Long May 2013 B2
8454594 Demarais et al. Jun 2013 B2
8460275 Taylor et al. Jun 2013 B2
8465419 Moriyama Jun 2013 B2
8465484 Davalos et al. Jun 2013 B2
8469993 Rothberg et al. Jun 2013 B2
8475359 Asada et al. Jul 2013 B2
8475361 Barlow et al. Jul 2013 B2
8475452 Van Wyk et al. Jul 2013 B2
8480657 Bakos Jul 2013 B2
8480689 Spivey et al. Jul 2013 B2
8485968 Weimer et al. Jul 2013 B2
8496574 Trusty et al. Jul 2013 B2
8500697 Kurth et al. Aug 2013 B2
8506564 Long et al. Aug 2013 B2
8512335 Cheng et al. Aug 2013 B2
8517921 Tremaglio et al. Aug 2013 B2
8518024 Williams et al. Aug 2013 B2
8518052 Burgermeister et al. Aug 2013 B2
8518062 Cole et al. Aug 2013 B2
8523884 Stam et al. Sep 2013 B2
8523939 Hausen Sep 2013 B1
8529563 Long et al. Sep 2013 B2
8540744 Spivey et al. Sep 2013 B2
8545396 Cover et al. Oct 2013 B2
8545450 Voegele et al. Oct 2013 B2
8551058 Measamer et al. Oct 2013 B2
8562513 Yamatani Oct 2013 B2
8562602 Azure Oct 2013 B2
8568410 Vakharia et al. Oct 2013 B2
8579176 Smith et al. Nov 2013 B2
8579897 Vakharia et al. Nov 2013 B2
8602970 Muyari et al. Dec 2013 B2
8603138 Faller et al. Dec 2013 B2
8608652 Voegele et al. Dec 2013 B2
8617156 Werneth et al. Dec 2013 B2
8623011 Spivey Jan 2014 B2
8632534 Pearson et al. Jan 2014 B2
8632563 Nagase et al. Jan 2014 B2
8636648 Gazdzinski Jan 2014 B2
8636650 Lee Jan 2014 B2
8636730 Keppel Jan 2014 B2
8640940 Ohdaira Feb 2014 B2
8641728 Stokes et al. Feb 2014 B2
8652150 Swain et al. Feb 2014 B2
8657174 Yates et al. Feb 2014 B2
8663236 Chen et al. Mar 2014 B2
8668686 Govari et al. Mar 2014 B2
8679003 Spivey Mar 2014 B2
8684967 Engel et al. Apr 2014 B2
8685058 Wilk Apr 2014 B2
8704923 Ogasawara et al. Apr 2014 B2
8715281 Barlow et al. May 2014 B2
8721658 Kahle et al. May 2014 B2
8723936 Amling et al. May 2014 B2
8727967 Weitzner May 2014 B2
8747401 Gonzalez et al. Jun 2014 B2
8753262 Sugiyama et al. Jun 2014 B2
8753335 Moshe et al. Jun 2014 B2
8764735 Coe et al. Jul 2014 B2
8771173 Fonger et al. Jul 2014 B2
8771260 Conlon et al. Jul 2014 B2
8774913 Demarais et al. Jul 2014 B2
8784436 Ho et al. Jul 2014 B2
8795161 Carter Aug 2014 B2
8821520 Schwemberger et al. Sep 2014 B2
8821532 Schaeffer Sep 2014 B2
8828031 Fox et al. Sep 2014 B2
8834461 Werneth et al. Sep 2014 B2
8845656 Skakoon et al. Sep 2014 B2
8858590 Shelton, IV et al. Oct 2014 B2
8876701 Surti et al. Nov 2014 B2
8876772 Weber et al. Nov 2014 B2
8880185 Hastings et al. Nov 2014 B2
8882786 Bearinger et al. Nov 2014 B2
8888792 Harris et al. Nov 2014 B2
8906035 Zwolinski et al. Dec 2014 B2
8911452 Skakoon et al. Dec 2014 B2
8920442 Sibbitt, Jr. et al. Dec 2014 B2
8926606 Davalos et al. Jan 2015 B2
8932208 Kendale et al. Jan 2015 B2
8939897 Nobis Jan 2015 B2
8956352 Mauch et al. Feb 2015 B2
8974374 Schostek et al. Mar 2015 B2
8986199 Weisenburgh, II et al. Mar 2015 B2
8992517 Davalos et al. Mar 2015 B2
9005198 Long et al. Apr 2015 B2
9011431 Long et al. Apr 2015 B2
9028483 Long et al. May 2015 B2
9036015 Verburgh et al. May 2015 B2
9049987 Conlon et al. Jun 2015 B2
9060782 Daniel et al. Jun 2015 B2
9066655 Stefanchik et al. Jun 2015 B2
9078662 Bakos et al. Jul 2015 B2
9084621 Weitzner et al. Jul 2015 B2
9089323 Bonutti et al. Jul 2015 B2
9125557 Lien et al. Sep 2015 B2
9125631 Smith et al. Sep 2015 B2
9125639 Mathis et al. Sep 2015 B2
9149172 Iddan et al. Oct 2015 B2
9155587 Willis et al. Oct 2015 B2
9186203 Spivey et al. Nov 2015 B2
9198733 Neal, II et al. Dec 2015 B2
9220526 Conlon Dec 2015 B2
9226772 Fox Jan 2016 B2
9233241 Long Jan 2016 B2
9248278 Crosby et al. Feb 2016 B2
9254169 Long et al. Feb 2016 B2
9265407 Goldfarb et al. Feb 2016 B2
9271796 Buysse et al. Mar 2016 B2
9277957 Long et al. Mar 2016 B2
9295485 Conlon et al. Mar 2016 B2
9308049 Dejima Apr 2016 B2
9314620 Long et al. Apr 2016 B2
9339328 Ortiz et al. May 2016 B2
9345462 Weitzner et al. May 2016 B2
9352152 Lindenthaler et al. May 2016 B2
9370341 Ceniccola et al. Jun 2016 B2
9375268 Long Jun 2016 B2
9427255 Griffith et al. Aug 2016 B2
9486241 Zeiner et al. Nov 2016 B2
9492148 Ginn et al. Nov 2016 B2
9545290 Tellio et al. Jan 2017 B2
9549719 Shohat et al. Jan 2017 B2
9566126 Weitzner et al. Feb 2017 B2
9572623 Long Feb 2017 B2
9598691 Davalos Mar 2017 B2
9627120 Scott et al. Apr 2017 B2
9668725 Beaven Jun 2017 B2
9694175 Tyson, Jr. Jul 2017 B2
9700334 Hinman et al. Jul 2017 B2
9788885 Long et al. Oct 2017 B2
9788888 Bakos et al. Oct 2017 B2
9788890 Toth et al. Oct 2017 B2
9808597 Vargas et al. Nov 2017 B2
9833282 Jun Dec 2017 B2
9833595 Gonzalez Dec 2017 B2
9861272 Pell et al. Jan 2018 B2
9883910 Conlon et al. Feb 2018 B2
20010023333 Wise et al. Sep 2001 A1
20020022857 Goldsteen et al. Feb 2002 A1
20020023353 Ting-Kung Feb 2002 A1
20020029055 Bonutti Mar 2002 A1
20020042562 Meron et al. Apr 2002 A1
20020068945 Sixto et al. Jun 2002 A1
20020082551 Yachia et al. Jun 2002 A1
20020095164 Andreas et al. Jul 2002 A1
20020133115 Gordon et al. Sep 2002 A1
20020138086 Sixto et al. Sep 2002 A1
20020165592 Glukhovsky et al. Nov 2002 A1
20030014090 Abrahamson Jan 2003 A1
20030018373 Eckhardt et al. Jan 2003 A1
20030069602 Jacobs et al. Apr 2003 A1
20030078471 Foley et al. Apr 2003 A1
20030083681 Moutafis et al. May 2003 A1
20030114731 Cadeddu et al. Jun 2003 A1
20030114732 Webler et al. Jun 2003 A1
20030120257 Houston et al. Jun 2003 A1
20030124009 Ravi et al. Jul 2003 A1
20030130656 Levin Jul 2003 A1
20030139646 Sharrow et al. Jul 2003 A1
20030153960 Chornenky Aug 2003 A1
20030158521 Ameri Aug 2003 A1
20030167062 Gambale et al. Sep 2003 A1
20030187351 Franck et al. Oct 2003 A1
20030225312 Suzuki et al. Dec 2003 A1
20030225332 Okada et al. Dec 2003 A1
20030229269 Humphrey Dec 2003 A1
20030229371 Whitworth Dec 2003 A1
20040002683 Nicholson et al. Jan 2004 A1
20040015190 Bernabei Jan 2004 A1
20040024414 Downing Feb 2004 A1
20040098007 Heiss May 2004 A1
20040101456 Kuroshima et al. May 2004 A1
20040104999 Okada Jun 2004 A1
20040133089 Kilcoyne et al. Jul 2004 A1
20040136779 Bhaskar Jul 2004 A1
20040138529 Wiltshire et al. Jul 2004 A1
20040138587 Lyons Jul 2004 A1
20040138747 Kaladelfos Jul 2004 A1
20040161451 Pierce et al. Aug 2004 A1
20040167545 Sadler et al. Aug 2004 A1
20040176699 Walker et al. Sep 2004 A1
20040186350 Brenneman et al. Sep 2004 A1
20040193009 Jaffe et al. Sep 2004 A1
20040193186 Kortenbach et al. Sep 2004 A1
20040193188 Francese Sep 2004 A1
20040193189 Kortenbach et al. Sep 2004 A1
20040193200 Dworschak et al. Sep 2004 A1
20040199052 Banik et al. Oct 2004 A1
20040199159 Lee et al. Oct 2004 A1
20040206859 Chong et al. Oct 2004 A1
20040210245 Erickson et al. Oct 2004 A1
20040225186 Horne et al. Nov 2004 A1
20040243108 Suzuki Dec 2004 A1
20040249367 Saadat et al. Dec 2004 A1
20040249394 Morris et al. Dec 2004 A1
20040249443 Shanley et al. Dec 2004 A1
20040254572 McIntyre et al. Dec 2004 A1
20040260315 Dell et al. Dec 2004 A1
20040260337 Freed Dec 2004 A1
20050004515 Hart et al. Jan 2005 A1
20050043690 Todd Feb 2005 A1
20050059963 Phan et al. Mar 2005 A1
20050059964 Fitz Mar 2005 A1
20050065509 Coldwell et al. Mar 2005 A1
20050070947 Franer et al. Mar 2005 A1
20050080435 Smith et al. Apr 2005 A1
20050085693 Belson et al. Apr 2005 A1
20050085832 Sancoff et al. Apr 2005 A1
20050090837 Sixto et al. Apr 2005 A1
20050096502 Khalili May 2005 A1
20050101837 Kalloo et al. May 2005 A1
20050101838 Camillocci et al. May 2005 A1
20050107663 Saadat et al. May 2005 A1
20050107664 Kalloo et al. May 2005 A1
20050119613 Moenning et al. Jun 2005 A1
20050124855 Jaffe et al. Jun 2005 A1
20050125010 Smith et al. Jun 2005 A1
20050131457 Douglas et al. Jun 2005 A1
20050137454 Saadat et al. Jun 2005 A1
20050143690 High Jun 2005 A1
20050143774 Polo Jun 2005 A1
20050143803 Watson et al. Jun 2005 A1
20050149087 Ahlberg et al. Jul 2005 A1
20050149096 Hilal et al. Jul 2005 A1
20050165272 Okada et al. Jul 2005 A1
20050165378 Heinrich et al. Jul 2005 A1
20050165411 Orban Jul 2005 A1
20050165429 Douglas et al. Jul 2005 A1
20050182429 Yamanouchi Aug 2005 A1
20050192478 Williams et al. Sep 2005 A1
20050192602 Manzo Sep 2005 A1
20050209624 Vijay Sep 2005 A1
20050215858 Vail Sep 2005 A1
20050216036 Nakao Sep 2005 A1
20050228224 Okada et al. Oct 2005 A1
20050228406 Bose Oct 2005 A1
20050240249 Tu et al. Oct 2005 A1
20050250987 Ewers et al. Nov 2005 A1
20050251176 Swanstrom et al. Nov 2005 A1
20050261711 Okada et al. Nov 2005 A1
20050267492 Poncet et al. Dec 2005 A1
20050272977 Saadat et al. Dec 2005 A1
20050274935 Nelson Dec 2005 A1
20050277956 Francese et al. Dec 2005 A1
20050288555 Binmoeller Dec 2005 A1
20050288730 Deem Dec 2005 A1
20060004406 Wehrstein et al. Jan 2006 A1
20060004409 Nobis et al. Jan 2006 A1
20060004410 Nobis et al. Jan 2006 A1
20060015009 Jaffe et al. Jan 2006 A1
20060015131 Kierce et al. Jan 2006 A1
20060020167 Sitzmann Jan 2006 A1
20060025654 Suzuki et al. Feb 2006 A1
20060025781 Young et al. Feb 2006 A1
20060025812 Shelton Feb 2006 A1
20060036267 Saadat et al. Feb 2006 A1
20060041188 Dirusso et al. Feb 2006 A1
20060058582 Maahs et al. Mar 2006 A1
20060064083 Khalaj et al. Mar 2006 A1
20060069424 Acosta et al. Mar 2006 A1
20060069429 Spence et al. Mar 2006 A1
20060074413 Behzadian Apr 2006 A1
20060089528 Tartaglia et al. Apr 2006 A1
20060095031 Ormsby May 2006 A1
20060100687 Fahey et al. May 2006 A1
20060111210 Hinman May 2006 A1
20060111703 Kunis et al. May 2006 A1
20060111704 Brenneman et al. May 2006 A1
20060129166 Lavelle Jun 2006 A1
20060135962 Kick et al. Jun 2006 A1
20060135971 Swanstrom et al. Jun 2006 A1
20060142652 Keenan Jun 2006 A1
20060142790 Gertner Jun 2006 A1
20060142798 Holman et al. Jun 2006 A1
20060149129 Watts et al. Jul 2006 A1
20060149131 Or Jul 2006 A1
20060149132 Iddan Jul 2006 A1
20060161190 Gadberry et al. Jul 2006 A1
20060167482 Swain et al. Jul 2006 A1
20060178560 Saadat et al. Aug 2006 A1
20060183975 Saadat et al. Aug 2006 A1
20060184161 Maahs et al. Aug 2006 A1
20060189844 Tien Aug 2006 A1
20060200005 Bjork et al. Sep 2006 A1
20060200121 Mowery Sep 2006 A1
20060200169 Sniffin Sep 2006 A1
20060200170 Aranyi Sep 2006 A1
20060217665 Prosek Sep 2006 A1
20060217742 Messerly et al. Sep 2006 A1
20060237023 Cox et al. Oct 2006 A1
20060241570 Wilk Oct 2006 A1
20060241691 Wilk Oct 2006 A1
20060247500 Voegele et al. Nov 2006 A1
20060247576 Poncet Nov 2006 A1
20060247663 Schwartz et al. Nov 2006 A1
20060253004 Frisch et al. Nov 2006 A1
20060259010 Stefanchik et al. Nov 2006 A1
20060259073 Miyamoto et al. Nov 2006 A1
20060264752 Rubinsky et al. Nov 2006 A1
20060264904 Kerby et al. Nov 2006 A1
20060270902 Igarashi et al. Nov 2006 A1
20060271042 Latterell et al. Nov 2006 A1
20060271102 Bosshard et al. Nov 2006 A1
20060276835 Uchida Dec 2006 A1
20060287644 Inganas et al. Dec 2006 A1
20060287666 Saadat et al. Dec 2006 A1
20070000550 Osinski Jan 2007 A1
20070005019 Okishige Jan 2007 A1
20070015965 Cox et al. Jan 2007 A1
20070032701 Fowler et al. Feb 2007 A1
20070051375 Milliman Mar 2007 A1
20070066869 Hoffman Mar 2007 A1
20070067017 Trapp Mar 2007 A1
20070073102 Matsuno et al. Mar 2007 A1
20070078439 Grandt et al. Apr 2007 A1
20070083192 Welch Apr 2007 A1
20070100375 Mikkaichi et al. May 2007 A1
20070100376 Mikkaichi et al. May 2007 A1
20070106113 Ravo May 2007 A1
20070106317 Shelton et al. May 2007 A1
20070112251 Nakhuda May 2007 A1
20070112342 Pearson et al. May 2007 A1
20070112385 Conlon May 2007 A1
20070112417 Shanley et al. May 2007 A1
20070118115 Artale et al. May 2007 A1
20070123840 Cox May 2007 A1
20070135803 Belson Jun 2007 A1
20070142706 Matsui et al. Jun 2007 A1
20070142710 Yokoi et al. Jun 2007 A1
20070142779 Duane et al. Jun 2007 A1
20070156028 Van Lue et al. Jul 2007 A1
20070161855 Mikkaichi et al. Jul 2007 A1
20070167901 Herrig et al. Jul 2007 A1
20070173686 Lin et al. Jul 2007 A1
20070173691 Yokoi et al. Jul 2007 A1
20070173869 Gannoe et al. Jul 2007 A1
20070173870 Zacharias Jul 2007 A2
20070173872 Neuenfeldt Jul 2007 A1
20070179525 Frecker et al. Aug 2007 A1
20070191904 Libbus et al. Aug 2007 A1
20070198057 Gelbart et al. Aug 2007 A1
20070203398 Bonadio et al. Aug 2007 A1
20070208336 Kim et al. Sep 2007 A1
20070208407 Gerdts et al. Sep 2007 A1
20070213754 Mikkaichi et al. Sep 2007 A1
20070225552 Segawa et al. Sep 2007 A1
20070233040 Macnamara et al. Oct 2007 A1
20070244356 Carrillo et al. Oct 2007 A1
20070244358 Lee Oct 2007 A1
20070255303 Bakos et al. Nov 2007 A1
20070260121 Bakos et al. Nov 2007 A1
20070260242 Dycus et al. Nov 2007 A1
20070260273 Cropper et al. Nov 2007 A1
20070260302 Igaki Nov 2007 A1
20070265494 Leanna et al. Nov 2007 A1
20070270629 Charles Nov 2007 A1
20070270907 Stokes et al. Nov 2007 A1
20070282165 Hopkins et al. Dec 2007 A1
20080004650 George Jan 2008 A1
20080015413 Barlow et al. Jan 2008 A1
20080021416 Arai et al. Jan 2008 A1
20080022927 Zhang et al. Jan 2008 A1
20080027387 Grabinsky Jan 2008 A1
20080033244 Matsui et al. Feb 2008 A1
20080058586 Karpiel Mar 2008 A1
20080065169 Colliou et al. Mar 2008 A1
20080082108 Skakoon et al. Apr 2008 A1
20080091068 Terliuc Apr 2008 A1
20080097159 Ishiguro Apr 2008 A1
20080097472 Agmon et al. Apr 2008 A1
20080103527 Martin et al. May 2008 A1
20080114384 Chang et al. May 2008 A1
20080125765 Berenshteyn et al. May 2008 A1
20080125774 Palanker et al. May 2008 A1
20080125796 Graham May 2008 A1
20080140069 Filloux et al. Jun 2008 A1
20080140071 Vegesna Jun 2008 A1
20080147056 van der Weide et al. Jun 2008 A1
20080150754 Quendt Jun 2008 A1
20080171907 Long et al. Jul 2008 A1
20080188710 Segawa et al. Aug 2008 A1
20080200755 Bakos Aug 2008 A1
20080200762 Stokes et al. Aug 2008 A1
20080200911 Long Aug 2008 A1
20080200933 Bakos et al. Aug 2008 A1
20080200934 Fox Aug 2008 A1
20080208213 Benjamin et al. Aug 2008 A1
20080214890 Motai et al. Sep 2008 A1
20080221587 Schwartz Sep 2008 A1
20080228213 Blakeney et al. Sep 2008 A1
20080230972 Ganley Sep 2008 A1
20080243148 Mikkaichi et al. Oct 2008 A1
20080262513 Stahler et al. Oct 2008 A1
20080262524 Bangera et al. Oct 2008 A1
20080262540 Bangera et al. Oct 2008 A1
20080275474 Martin et al. Nov 2008 A1
20080287801 Magnin et al. Nov 2008 A1
20080300461 Shaw et al. Dec 2008 A1
20080300571 LePivert Dec 2008 A1
20080306493 Shibata et al. Dec 2008 A1
20080309758 Karasawa et al. Dec 2008 A1
20080319436 Daniel Dec 2008 A1
20090030278 Minakuchi Jan 2009 A1
20090054728 Trusty Feb 2009 A1
20090062788 Long et al. Mar 2009 A1
20090062795 Vakharia et al. Mar 2009 A1
20090078736 Van Lue Mar 2009 A1
20090082627 Karasawa et al. Mar 2009 A1
20090093690 Yoshizawa Apr 2009 A1
20090112059 Nobis Apr 2009 A1
20090112063 Bakos et al. Apr 2009 A1
20090131751 Spivey et al. May 2009 A1
20090143639 Stark Jun 2009 A1
20090143649 Rossi Jun 2009 A1
20090143794 Conlon et al. Jun 2009 A1
20090163770 Torrie et al. Jun 2009 A1
20090177219 Conlon Jul 2009 A1
20090182332 Long et al. Jul 2009 A1
20090192344 Bakos et al. Jul 2009 A1
20090192534 Ortiz et al. Jul 2009 A1
20090198212 Timberlake et al. Aug 2009 A1
20090198231 Esser et al. Aug 2009 A1
20090210000 Sullivan et al. Aug 2009 A1
20090221873 McGrath Sep 2009 A1
20090228001 Pacey Sep 2009 A1
20090259105 Miyano et al. Oct 2009 A1
20090281559 Swain et al. Nov 2009 A1
20090287236 Bakos et al. Nov 2009 A1
20090292167 Kimoto Nov 2009 A1
20090306470 Karasawa et al. Dec 2009 A1
20090322864 Karasawa et al. Dec 2009 A1
20100010294 Conlon et al. Jan 2010 A1
20100010298 Bakos et al. Jan 2010 A1
20100010303 Bakos Jan 2010 A1
20100023032 Granja Filho Jan 2010 A1
20100036198 Tacchino et al. Feb 2010 A1
20100048990 Bakos Feb 2010 A1
20100049223 Granja Filho Feb 2010 A1
20100056862 Bakos Mar 2010 A1
20100076451 Zwolinski et al. Mar 2010 A1
20100081875 Fowler et al. Apr 2010 A1
20100113872 Asada et al. May 2010 A1
20100121362 Clague et al. May 2010 A1
20100130817 Conlon May 2010 A1
20100152539 Ghabrial et al. Jun 2010 A1
20100152725 Pearson et al. Jun 2010 A1
20100160906 Jarrard Jun 2010 A1
20100191050 Zwolinski Jul 2010 A1
20100191267 Fox Jul 2010 A1
20100198248 Vakharia Aug 2010 A1
20100210906 Wendlandt Aug 2010 A1
20100217367 Belson Aug 2010 A1
20100249700 Spivey Sep 2010 A1
20100256628 Pearson Oct 2010 A1
20100268025 Belson Oct 2010 A1
20100286791 Goldsmith Nov 2010 A1
20100298642 Trusty et al. Nov 2010 A1
20100312056 Galperin et al. Dec 2010 A1
20100331622 Conlon Dec 2010 A2
20110077476 Rofougaran et al. Mar 2011 A1
20110087224 Cadeddu et al. Apr 2011 A1
20110093009 Fox Apr 2011 A1
20110098694 Long Apr 2011 A1
20110098704 Long et al. Apr 2011 A1
20110112434 Ghabrial et al. May 2011 A1
20110112527 Hamilton, Jr. et al. May 2011 A1
20110115891 Trusty May 2011 A1
20110152610 Trusty et al. Jun 2011 A1
20110152878 Trusty et al. Jun 2011 A1
20110152923 Fox Jun 2011 A1
20110160514 Long et al. Jun 2011 A1
20110190764 Long et al. Aug 2011 A1
20110245619 Holcomb Oct 2011 A1
20110284014 Cadeddu et al. Nov 2011 A1
20120029335 Sudam et al. Feb 2012 A1
20120088965 Stokes et al. Apr 2012 A1
20120089089 Swain et al. Apr 2012 A1
20120089093 Trusty Apr 2012 A1
20120101331 Gilad et al. Apr 2012 A1
20120101413 Beetel et al. Apr 2012 A1
20120109122 Arena et al. May 2012 A1
20120116155 Trusty May 2012 A1
20120116266 Houser et al. May 2012 A1
20120149981 Khait et al. Jun 2012 A1
20120191075 Trusty Jul 2012 A1
20120191076 Voegele et al. Jul 2012 A1
20120197246 Mauch Aug 2012 A1
20130030430 Stewart et al. Jan 2013 A1
20130090666 Hess et al. Apr 2013 A1
20130158348 Nobis et al. Jun 2013 A1
20130245356 Fernandez et al. Sep 2013 A1
20130267834 McGee Oct 2013 A1
20130331649 Khait et al. Dec 2013 A1
20140039491 Bakos et al. Feb 2014 A1
20140052216 Long et al. Feb 2014 A1
20140121678 Trusty et al. May 2014 A1
20140243597 Weisenburgh, II et al. Aug 2014 A1
20150032132 Harris et al. Jan 2015 A1
20150100064 Skakoon et al. Apr 2015 A1
20150230858 Long et al. Aug 2015 A1
20150265342 Long et al. Sep 2015 A1
20160074056 Conlon Mar 2016 A1
20160100879 Long Apr 2016 A1
20160296280 Long Oct 2016 A1
20160338731 Griffith et al. Nov 2016 A1
20170049508 Long et al. Feb 2017 A1
20170086937 Tellio et al. Mar 2017 A1
20170119465 Long et al. May 2017 A1
20180042661 Long et al. Feb 2018 A1
Foreign Referenced Citations (191)
Number Date Country
666310 Feb 1996 AU
3008120 Sep 1980 DE
4323585 Jan 1995 DE
19713797 Oct 1997 DE
19757056 Aug 2008 DE
102006027873 Oct 2009 DE
0086338 Aug 1983 EP
0286415 Oct 1988 EP
0499491 Aug 1992 EP
0589454 Mar 1994 EP
0464479 Mar 1995 EP
0529675 Feb 1996 EP
0773003 May 1997 EP
0621009 Jul 1997 EP
0724863 Jul 1999 EP
0760629 Nov 1999 EP
0818974 Jul 2001 EP
1281356 Feb 2003 EP
0947166 May 2003 EP
0836832 Dec 2003 EP
1402837 Mar 2004 EP
0744918 Apr 2004 EP
0931515 Aug 2004 EP
0941128 Oct 2004 EP
1411843 Oct 2004 EP
1150614 Nov 2004 EP
1481642 Dec 2004 EP
1493391 Jan 2005 EP
0848598 Feb 2005 EP
1281360 Mar 2005 EP
1568330 Aug 2005 EP
1452143 Sep 2005 EP
1616527 Jan 2006 EP
1006888 Mar 2006 EP
1629764 Mar 2006 EP
1013229 Jun 2006 EP
1721561 Nov 2006 EP
1153578 Mar 2007 EP
1334696 Mar 2007 EP
1836971 Sep 2007 EP
1836980 Sep 2007 EP
1854421 Nov 2007 EP
1857061 Nov 2007 EP
1875876 Jan 2008 EP
1891881 Feb 2008 EP
1902663 Mar 2008 EP
1477106 Jun 2008 EP
1949844 Jul 2008 EP
1518499 Aug 2008 EP
1582138 Sep 2008 EP
1709918 Oct 2008 EP
1985226 Oct 2008 EP
1994904 Nov 2008 EP
1707130 Dec 2008 EP
1477104 Jan 2009 EP
0723462 Mar 2009 EP
1769749 Nov 2009 EP
2135545 Dec 2009 EP
1769766-61 Feb 2010 EP
1493397 Sep 2011 EP
2659847 Nov 2013 EP
2731610 Sep 1996 FR
330629 Jun 1930 GB
2335860 Oct 1999 GB
2403909 Jan 2005 GB
2421190 Jun 2006 GB
2443261 Apr 2008 GB
S63309252 Dec 1988 JP
H043896 Feb 1992 JP
H06269460 Sep 1994 JP
H0829699 Feb 1996 JP
H0975365 Mar 1997 JP
H1024049 Jan 1998 JP
3007713 Feb 2000 JP
2000107197 Apr 2000 JP
2000245683 Sep 2000 JP
2001526072 Dec 2001 JP
2002369791 Dec 2002 JP
2003088494 Mar 2003 JP
2003235852 Aug 2003 JP
2004033525 Feb 2004 JP
2004065745 Mar 2004 JP
2005121947 May 2005 JP
2005261514 Sep 2005 JP
2005296063 Oct 2005 JP
2006517843 Aug 2006 JP
2006297005 Nov 2006 JP
2006343510 Dec 2006 JP
2007020806 Feb 2007 JP
2007125264 May 2007 JP
2007516792 Jun 2007 JP
2010503496 Feb 2010 JP
2012515018 Jul 2012 JP
5646674 Dec 2014 JP
1021295 Feb 2004 NL
194230 May 1967 SU
980703 Dec 1982 SU
WO-8401707 May 1984 WO
WO-8607543 Dec 1986 WO
WO-9213494 Aug 1992 WO
WO-9310850 Jun 1993 WO
WO-9320760 Oct 1993 WO
WO-9320765 Oct 1993 WO
WO-9422383 Oct 1994 WO
WO-9509666 Apr 1995 WO
WO-9622056 Jul 1996 WO
WO-9627331 Sep 1996 WO
WO-9639946 Dec 1996 WO
WO-9712557 Apr 1997 WO
WO-9801080 Jan 1998 WO
WO-9900060 Jan 1999 WO
WO-9909919 Mar 1999 WO
WO-9917661 Apr 1999 WO
WO-9930622 Jun 1999 WO
WO-0022996 Apr 2000 WO
WO-0035358 Jun 2000 WO
WO-0068665 Nov 2000 WO
WO-0110319 Feb 2001 WO
WO-0126708 Apr 2001 WO
WO-0141627 Jun 2001 WO
WO-0158360 Aug 2001 WO
WO-0211621 Feb 2002 WO
WO-0234122 May 2002 WO
WO-02094082 Nov 2002 WO
WO-03045260 Jun 2003 WO
WO-03047684 Jun 2003 WO
WO-03059412 Jul 2003 WO
WO-03078721 Sep 2003 WO
WO-03081761 Oct 2003 WO
WO-03082129 Oct 2003 WO
WO-2004006789 Jan 2004 WO
WO-2004028613 Apr 2004 WO
WO-2004037123 May 2004 WO
WO-2004037149 May 2004 WO
WO-2004052221 Jun 2004 WO
WO-2004086984 Oct 2004 WO
WO-2005009211 Feb 2005 WO
WO-2005018467 Mar 2005 WO
WO-2005037088 Apr 2005 WO
WO-2005048827 Jun 2005 WO
WO-2005065284 Jul 2005 WO
WO-2005097019 Oct 2005 WO
WO-2005097234 Oct 2005 WO
WO-2005112810 Dec 2005 WO
WO-2005120363 Dec 2005 WO
WO-2005122866 Dec 2005 WO
WO-2006007399 Jan 2006 WO
WO-2006012630 Feb 2006 WO
WO-2006040109 Apr 2006 WO
WO-2006041881 Apr 2006 WO
WO-2006060405 Jun 2006 WO
WO-2006110733 Oct 2006 WO
WO-2006113216 Oct 2006 WO
WO-2007013059 Feb 2007 WO
WO-2007014063 Feb 2007 WO
WO-2007035537 Mar 2007 WO
WO-2007048085 Apr 2007 WO
WO-2007063550 Jun 2007 WO
WO-2007100067 Sep 2007 WO
WO-2007109171 Sep 2007 WO
WO-2007135577 Nov 2007 WO
WO-2007143200 Dec 2007 WO
WO-2007144004 Dec 2007 WO
WO-2008005433 Jan 2008 WO
WO-2008033356 Mar 2008 WO
WO-2008034103 Mar 2008 WO
WO-2008041225 Apr 2008 WO
WO-2008076337 Jun 2008 WO
WO-2008076800 Jun 2008 WO
WO-2008079440 Jul 2008 WO
WO-2008080062 Jul 2008 WO
WO-2008101075 Aug 2008 WO
WO-2008101086 Aug 2008 WO
WO-2008102154 Aug 2008 WO
WO-2008108863 Sep 2008 WO
WO-2008151237 Dec 2008 WO
WO-2009021030 Feb 2009 WO
WO-2009027065 Mar 2009 WO
WO-2009029065 Mar 2009 WO
WO-2009032623 Mar 2009 WO
WO-2009036457 Mar 2009 WO
WO-2009121017 Oct 2009 WO
WO-2009132190 Oct 2009 WO
WO-2010027688 Mar 2010 WO
WO-2010056716 May 2010 WO
WO-2010080974 Jul 2010 WO
WO-2010088481 Aug 2010 WO
WO-2012031204 Mar 2012 WO
WO-2012068505 May 2012 WO
WO-2012071526 May 2012 WO
WO-2013044378 Apr 2013 WO
Non-Patent Literature Citations (66)
Entry
Rutala et al. “Guideline for Disinfection and Sterilization in Healthcare Facilities, 2008” (available at http://www.cdc.gov/hicpac/Disinfection_Sterilization/13_11sterilizingPractices.html).
Bewlay et al., “Spinning” in ASM Handbook, vol. 14B, Metalworking: Sheet Forming (2006).
Michael S. Kavic, M.D., “Natural Orifice Translumenal Endoscopic Surgery: “NOTES””, JSLS, vol. 10, pp. 133-134 (2006).
Ethicon, Inc., “Wound Closure Manual: Chapter 3 (The Surgical Needle),” 15 pages, (1994).
Guido M. Sclabas, M.D., et al., “Endoluminal Methods for Gastrotomy Closure in Natural Orifice TransEnteric Surgery (NOTES),” Surgical Innovation, vol. 13, No. 1, pp. 23-30, Mar. 2006.
Fritscher-Ravens, et al., “Transgastric Gastropexy and Hiatal Hernia Repair for GERD Under EUS Control: a Porcine Model,” Gastrointestinal Endoscopy, vol. 59, No. 1, pp. 89-95, 2004.
Kennedy, et al., “High-Burst-Strength, Feedback-Controlled Bipolar Vessel Sealing,” Surgical Endoscopy, vol. 12, pp. 876-878 (1998).
Collins et al., “Local Gene Therapy of Solid Tumors with GM-CSF and B7-1 Eradicates Both Treated and Distal Tumors,” Cancer Gene Therapy, vol. 13, pp. 1061-1071 (2006).
K. Sumiyama et al., “Transesophageal Mediastinoscopy by Submucosal Endoscopy With Mucosal Flap Safety Value Technique,” Gastrointest Endosc., Apr. 2007, vol. 65(4), pp. 679-683 (Abstract).
K. Sumiyama et al., “Submucosal Endoscopy with Mucosal Flap Safety Valve,” Gastrointest Endosc. Apr. 2007, vol. 65(4) pp. 694-695 (Abstract).
K. Sumiyama et al., “Transgastric Cholecystectomy: Transgastric Accessibility to the Gallbladder Improved with the SEMF Method and a Novel Multibending Therapeutic Endoscope,” Gastrointest Endosc., Jun. 2007, vol. 65(7), pp. 1028-1034 (Abstract).
K. Sumiyama et al., “Endoscopic Caps,” Tech. Gastrointest. Endosc., vol. 8, pp. 28-32, 2006.
I. Fraser, “An Historical Perspective on Mechanical Aids in Intestinal Anastamosis,” Surg. Gynecol. Obstet. (Oct. 1982), vol. 155, pp. 566-574.
M.E. Ryan et al., “Endoscopic Intervention for Biliary Leaks After Laparoscopic Cholecystectomy: A Multicenter Review,” Gastrointest. Endosc., vol. 47(3), 1998, pp. 261-266.
J.W. Hazey et al., “Natural Orifice Transgastric Endoscopic Peritoneoscopy in Humans: Initial Clinical Trial,” Surg Endosc, (Jan. 2008), vol. 22(1), pp. 16-20.
N. Chopita et al., “Endoscopic Gastroenteric Anastamosis Using Magnets,” Endoscopy, (2005), vol. 37(4), pp. 313-317.
C. Cope et al., “Long Term Patency of Experimental Magnetic Compression Gastroenteric Anastomoses Achieved with Covered Stents,” Gastrointest Endosc, (2001), vol. 53, pp. 780-784.
H. Okajima et al., “Magnet Compression Anastamosis for Bile Duct Stenosis After Duct to Duct Biliary Reconstruction in Living Donor Liver Transplantation,” Liver Transplantation (2005), pp. 473-475.
A. Fritscher-Ravens et al., “Transluminal Endosurgery: Single Lumen Access Anastamotic Device for Flexible Endoscopy,” Gastrointestinal Endosc, (2003), vol. 58(4), pp. 585-591.
P. O'Neill, M.D. et al., “Nonsuture Intestinal Anastomosis,” Am J. Surg, (1962), vol. 104, pp. 761-767.
C.P. Swain, M.D. et al., “Anastomosis at Flexible Endoscopy: An Experimental Study of Compression Button Gastrojejunostomy,” Gastrointest Endosc, (1991), vol. 37, pp. 628-632.
USGI® EndoSurgical Operating System—g-Prox® Tissue Grasper/Approximation Device; [online] URL: http://www.usgimedical.com/eos/components-gprox.htm—accessed May 30, 2008 (2 pages).
Printout of web page—http://www.vacumed.com/zcom/product/Product.do?compid=27&prodid=852, #51XX Low-Cost Permanent Tubes 2MM ID, Smooth Interior Walls, VacuMed, Ventura, California, Accessed Jul. 24, 2007.
Endoscopic Retrograde Cholangiopancreatogram (ERCP); [online] URL: http://www.webmd.com/digestive-disorders/endoscopic-retrograde-cholangiopancreatogram-ercp.htm; last updated: Apr. 30, 2007; accessed: Feb. 21, 2008 (6 pages).
ERCP; Jackson Siegelbaum Gastroenterology; [online] URL: http://www.gicare.com/pated/epdgs20.htm; accessed Feb. 21, 2008 (3 pages).
D.G. Fong et al., “Transcolonic Ventral Wall Hernia Mesh Fixation in a Porcine Model,” Endoscopy 2007; 39: 865-869.
D.B. Nelson, MD et al., “Endoscopic Hemostatic Devices,” Gastrointestinal Endoscopy, vol. 54, No. 6, 2001, pp. 833-840.
CRE™ Pulmonary Balloon Dilator; [online] URL: http://www.bostonscientific.com/Device.bsci?page=HCP_Overview&navRe1Id=1000.1003&method=D . . . , accessed Jul. 18, 2008 (4 pages).
J.D. Paulson, M.D., et al., “Development of Flexible Culdoscopy,” The Journal of the American Association of Gynecologic Laparoscopists, Nov. 1999, vol. 6, No. 4, pp. 487-490.
H. Seifert, et al., “Retroperitoneal Endoscopic Debridement for Infected Peripancreatic Necrosis,” The Lancet, Research Letters, vol. 356, Aug. 19, 2000, pp. 653-655.
D. Wilhelm et al., “An Innovative, Safe and Sterile Sigmoid Access (ISSA) for NOTES,” Endoscopy 2007, vol. 39, pp. 401-406.
Nakazawa et al., “Radiofrequency Ablation of Hepatocellular Carcinoma: Correlation Between Local Tumor Progression After Ablation and Ablative Margin,” AJR, 188, pp. 480-488 (Feb. 2007).
Miklavcic et al., “A validated model of in vivo electric field distribution in tissues for electrochemotherapy and for DNA electrotransfer for gene therapy,” Biochimica et Biophysica Acta, 1523, pp. 73-83 (2000).
Evans, “Ablative and cathether-delivered therapies for colorectal liver metastases (CRLM),” EJSO, 33, pp. S64-S75 (2007).
Wong et al., “Combined Percutaneous Radiofrequency Ablation and Ethanol Injection for Hepatocellular Carcinoma in High-Risk Locations,” AJR, 190, pp. W187-W195 (2008).
Heller et al., “Electrically mediated plasmid DNA delivery to hepatocellular carcinomas in vivo,” Gene Therapy, 7, pp. 826-829 (2000).
Weaver et al., “Theory of electroporation: A review,” Bioelectrochemistry and Bioenergetics, 41, pp. 135-160 (1996).
Link et al., “Regional Chemotherapy of Nonresectable Colorectal Liver Metastases with Mitoxanthrone, 5-Fluorouracil, Folinic Acid, and Mitomycin C May Prolong Survival,” Cancer, 92, pp. 2746-2753 (2001).
Guyton et al., “Membrane Potentials and Action Potentials,” W.B. Sanders, ed. Textbook of Medical Physiology, p. 56 (2000).
Guyton et al., “Contraction of Skeletal Muscle,” Textbook of Medical Physiology, pp. 82-84 (2000).
“Ethicon Endo-Surgery Studies Presented At DDW Demonstrate Potential of Pure NOTES Surgery With Company's Toolbox,” Jun. 3, 2009 Press Release; URL http://www.jnj.com/connect/news/product/20090603_120000; accessed Aug. 28, 2009 (3 pages).
Castellvi et al., “Hybrid Transvaginal NOTES Sleeve Gastrectomy in a Porcine Model Using a Magnetically Anchored Camera and Novel Instrumentation,” Poster submitted along with Abstract at SAGES Annual Meeting in Phoenix, AZ, Apr. 22, 2009 (1 page).
Hakko Retractors, obtained Aug. 25, 2009 (5 pages).
Zadno et al., “Linear Superelasticity in Cold-Worked NI-TI,” Engineering Aspects of Shape Memory Alloys, pp. 414-419 (1990).
How Stuff Works “How Smart Structures Will Work,” http://science.howstuffworks.com/engineering/structural/smart-structure1.htm; accessed online Nov. 1, 2011 (3 pages).
Stanway, Smart Fluids: Current and Future Developments. Material Science and Technology, 20, pp. 931-939, 2004; accessed online Nov. 1, 2011 at http://www.dynamics.group.shef.ac.uk/smart/smart.html (7 pages).
Instant Armor: Science Videos—Science News—ScienCentral; http://www.sciencentral.com/articles./view.php3?article_id=218392121; accessed online Nov. 1, 2011 (2 pages).
Widera et al., “Increased DNA Vaccine Delivery and Immunogenicity by Electroporation in Vivo,” The Journal of Immunology, 164, pp. 4635-4640 (2000).
Mulier et al., “Radiofrequency Ablation Versus Resection for Resectable Colorectal Liver Metastases: Time for a Randomized Trial?” Annals of Surgical Oncology, 15(1), pp. 144-157 (2008).
Z-Offset Technique Used in the Introduction of Trocar During Laparoscopic Surgery, M.S. Hershey NOTES Presentation to EES NOTES Development Team, Sep. 27, 2007.
J.B. Murphy, M.D., “Cholecysto-Intestinal, Gastro-Intestinal, Entero-Intestinal Anastomosis, and Approximation Without Sutures (original research),” Med Rec, (Dec. 10, 1892), vol. 42(24), pp. 665-676.
Edd, et al., “In Vivo Results of a New Focal Tissue Ablation Technique: Irreversible Electroporation,” IEEE Trans Biomed Eng, vol. 53, pp. 1409-1415, 2006.
Ogando, “Prototype Tools That Go With the Flow,” Design News, 2 pages, Jul. 17, 2006.
Castellvi et al., “Hybrid Transvaginal NOTES Sleeve Gastrectomy in a Porcine Model Using a Magnetically Anchored Camera and Novel Instrumentation,” Abstract submitted along with Poster at SAGES Annual Meeting in Phoenix, AZ, Apr. 22, 2009 (1 page).
OCTO Port Modular Laparoscopy System for Single Incision Access, Jan. 4, 2010; URL http://www.medgadget.com/archives/2010/01/octo_port_modular_laparo . . . ; accessed Jan. 5, 2010 (4 pages).
“Ethicon Endo-Surgery Novel Investigational Notes and SSL Devices Featured in 15 Presentations at Sages,” Apr. 22, 2009 Press Release; URL http://www.jnj.com/connect/news/all/20090422_152000; accessed Aug. 28, 2009 (3 pages).
B. Rubinsky, Ph.D., “Irreversible Electroporation in Medicine,” Technology in Cancer Research and Treatment, vol. 6, No. 4, Aug. 2007, pp. 255-259.
Davalos, et al., “Tissue Ablation with Irreversible Electroporation,” Annals of Biomedical Engineering, 33.2 (2005): 223-231.
C. Cope, “Creation of Compression Gastroenterostomy by Means of the Oral, Percutaneous, or Surgical Introduction of Magnets: Feasibility Study in Swine,” J. Vasc Interv Radiol, (1995), vol. 6(4), pp. 539-545.
Schoenbach et al. “Bacterial Decontamination of Liquids with Pulsed Electric Fields” IEEE Transactions on Dielectrics and Electrical Insulation. vol. 7 No. 5. Oct. 2000, pp. 637-645.
G.A. Hallenbeck, M.D. et al., “An Instrument for Colorectal Anastomosis Without Sutrues,” Dis Col Rectum, (1963), vol. 5, pp. 98-101.
Maxim Integrated Application Note 3977: Class D Amplifiers: Fundamentals of Operation and Recent Developments, Jan. 31, 2007.
T. Hardy, Jr., M.D. et al., “A Biofragmentable Ring for Sutureless Bowel Anastomosis. An Experimental Study,” Dis Col Rectum, (1985), vol. 28, pp. 484-490.
Jolly et al., Properties and Applications of Commercial Magneto rheological Fluids. SPIE 5th Annual Int. Symposium on Smart Structures and Materials, 1998 (18 pages).
F.N. Denans, Nouveau Procede Pour La Guerison Des Plaies Des Intestines. Extrait Des Seances De La Societe Royale De Medecine De Marseille, Pendant Le Mois De Dec. 1825, et le Premier Tremestre De 1826, Séance Du Feb. 24, 1826. Recueil De La Societe Royale De Medecin De Marseille. Marseille: Impr. D'Achard, 1826; 1:127-31. (with English translation).
K.E. Mönkemüller, M.D., et al., “Transmural Drainage of Pancreatic Fluid Collections Without Electrocautery Using the Seldinger Technique,” Gastrointestinal Endoscopy, vol. 48, No. 2, 1998, pp. 195-200, (Accepted Mar. 31, 1998).
Related Publications (1)
Number Date Country
20160128759 A1 May 2016 US
Divisions (1)
Number Date Country
Parent 13036895 Feb 2011 US
Child 14995728 US